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Abstract
EFFECTS OF HIV-1 TAT AND DRUGS OF ABUSE ON ANTIRETROVIRAL
PENETRATION INSIDE DIFFERENT CNS CELL TYPES
By Sulay Patel B.Pharm, M.S

A dissertation submitted in partial fulfillment of the requirements for the degree
of Doctor of Philosophy at Virginia Commonwealth University
Virginia Commonwealth University, 2018
Major Director: Dr. MaryPeace McRae, Department of Pharmacotherapy and
Outcome Sciences.

Human immunodeficiency (HIV) infection can result in neurocognitive deficits in about
one-half of infected individuals. Despite excellent systemic effectiveness, restricted
antiretroviral penetration across the blood-brain barrier (BBB) is a major limitation in
fighting HIV infection within the central nervous system (CNS). Drug abuse exacerbates
cognitive impairment and pathologic CNS changes in HIV-infected individuals. This work
investigates the effects of the HIV-1 protein, Tat, and drugs of abuse on factors affecting
drug penetration into the brain.
Firstly, an in vitro model of the blood-brain barrier was built to study effects of HIV-1 Tat
and methamphetamine (Meth) on integrity and function of the BBB, in turn how HIV-1 Tat
and meth will affect antiretroviral penetration into the brain. We found that co-exposure
8

HIV-1 Tat and Meth results in inhibition or impairment of P-glycoprotein activity at the
BBB. Also, simultaneous inhibition of P-glycoprotein (P-gp) and Multidrug Resistant
Protein -1 (MRP-1), by verapamil and MK-571 causes an increase in accumulation of
atazanavir inside the primary human brain endothelial cells.
Secondly, we developed and validated the method for simultaneous determination of
tenofovir, emtricitabine, and dolutegravir in cell extracts of CNS cells. This method was
used to study how HIV-1 Tat and/or morphine affects antiretroviral penetration in CNS
cells like human brain microvascular endothelial cells, human astrocytes, human
microglia, and human pericytes. We found that in untreated cells, accumulation of
antiretroviral drugs was higher in hCMEC/D3 cells compared to other CNS cell types.
Also, HIV-1 Tat and/or morphine had no significant effect on antiretroviral penetration
amongst these cell types. Overall, the rank order of intracellular accumulation observed
in treated and untreated cells was dolutegravir > emtricitabine > tenofovir.
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INTRODUCTION
History and Origin of HIV-1 infection
Human immunodeficiency virus -1 (HIV-1) is a lentivirus, belonging to the retroviral family,
and an etiologic agent for Acquired Immunodeficiency Syndrome (AIDS). It was first
recognized in 1981 when young homosexual men were reported of having opportunistic
infections (Pneumocystis carinii pneumonia, cytomegalovirus-associated retinitis, and
cryptococcal meningitis) and rare malignancies (non-Hodgkin’s lymphoma and Kaposi’s
sarcoma) (1). All the affected individuals showed significant reductions in the CD4 T
lymphocyte counts, resulting in the impaired immune system. In 1983, Montaigner and
colleagues at The Pasteur Institute isolated a virus from the lymph node of an
asymptomatic patient, who had lymphadenopathy (2). During the same time, Gallo and
colleagues at National Institute of Health (NIH) reported the isolation of a retrovirus from
an AIDS patient and named it Human T-cell Leukemia Virus Type III, which was
subsequently named as Human Immunodeficiency Virus (HIV-1) (3). HIV-1 comprises of
four different subgroups of virus, namely, M group (Main group), which is the pandemic
virus responsible for 98% of global viral isolates, Group O (Outlier group), Group N (nonM, non-O group), and Group P. HIV-1 from group M further consist of nine clades (A, B,
C, D, E, F, J, and K) and 49 circulating recombinant forms (CRFs) (4). The HIV-1 virus
is phylogenetically evolved from SIVcpzPtt from central chimpanzee subspecies, which
is the source of human and gorilla infection. It is thought that cross-species transfer of
HIV to human happened due to exposure to body fluids of the infected ape during
bushmeat hunting (5).
13

Human Immunodeficiency Virus -2 (HIV-2) is related to HIV-1, but it differs considerably
in virulence, transmission rates, and phylogenetic origin (6). HIV-2 is evolved from sooty
mangabey monkeys, and it is endemic to West Africa (7). The scope of this work will focus
on HIV-1 and HIV-1 related proteins.
HIV-1 Transmission and Epidemiology

HIV-1 is transmitted through the following major routes:
1) Sexual Transmission: Anal sex is the highest risk factor for transmitting HIV in
both men and women (8). Vaginal sex has a comparatively lower risk, and oral sex
has little or no risk for transmitting HIV (8). Sexual transmission can also lead to
other sexually transmitted infections.
2) Injection Drug Use (IDU): Injection drug use and HIV are interlinked epidemics. In
2016, individuals who injected drugs accounted for 9% of all HIV diagnoses (9).
Most of these transmissions occurred through exchanging needles and risky
sexual behaviors under the influence of drugs (9). Recently in 2014, in Scott
County, Indiana, there were instances of HIV-1 outbreak reported due to sharing
of needles in people who abuse prescription opioids (10).
3) Mother- to- Child Transmission: Globally, about 1.8 million children are living with
HIV (11). Of which, more than 90% of these children were either infected in utero,
at birth or through feeding of breast milk (9). With the advent of antiretroviral drugs,
perinatal HIV has significantly reduced. Mostly, mother to child transmission is
observed in sub-Saharan countries mostly due to poor availability of antiretroviral
drugs (12).
4) Blood Transfusion: Occasionally, HIV transmission is caused by blood transfusion.
14

According to a UNAIDS Data of 2018, 36.7 million people worldwide are living with HIV.
There were 1.8 million new HIV infections reported in 2016 and 0.94 million deaths due
to AIDS (11). According to the CDC HIV surveillance report, there are about 1.2 million
people in the USA and dependent areas living with HIV in 2016. There were 38,500 new
cases of HIV diagnoses were reported in 2016 (9). The highest rate of diagnoses and
incidence were reported in southern states, mid-Atlantic, and California. African
Americans, who represent 18% of the population, accounted for 44% of new HIV
diagnoses, while Hispanics/Latinos, who represent 18% of the population, accounted for
25% new diagnoses. Men who have sex with men had 70% of new infections, 24% of
new infections were in heterosexual individuals, and 6% were among people who inject
drugs. These prevalence estimates illustrate significant disparity based on race and
sexual orientation.
HIV-1 Biology and Clinical Stages of HIV-1 Infection

HIV-1 is a spherical virus with a nine kilobase genome consisting of gag, pol, env, vif,
vpu, vpr, tat, rev, and nef genes (13). HIV-1 primarily infects cells with CD4 receptors.
However, HIV-1 viral isolates were found in the cells, which do not requires CD4 receptors
to infect cells (14). The life cycle of HIV-1 from its entry into the cell maturation can be
explained through nine steps or stages as shown in (Fig 1).
Step 1: Binding of gp120
HIV-1 envelope protein is encoded by HIV-1 env gene (15). It is synthesized as a
precursor protein, which is processed by host proteases into gp120 and gp41. The
unprocessed protein has been designated as gp160 based on its molecular weight. HIV15

1 envelope protein comprises of heavily glycosylated trimers of gp120 (surface unit) and
gp41 (transmembrane unit) heterodimers, which are non-covalently linked with each
other. Surface glycoprotein (gp120) is responsible for receptor binding on the host cell
membrane; it contains five conserved domains (C1-C5) and five variable loops (V1-V5)
(16). Variable loops lie on the surface of gp120 and are thought to play a vital role in
immune evasion and coreceptor binding. HIV-1 primarily infects CD4 receptor containing
T cells and macrophages (17). Initially, interactions between several attachment factors
and envelope proteins bring virus close to CD4 receptor and coreceptor on the host cell,
increasing efficiency of viral infection. These interactions can be either non-specific,
between envelope proteins and negatively charged cell surface heparan sulfate
proteoglycans (18) or specific between envelope protein and α4β7 integrin and DC-SIGN
(19, 20). These interactions lead to binding of gp120 to CD4 receptor containing target
cells.
Step 2: Co-receptor Binding
Binding of HIV-1 envelope protein (gp120) to the CD4 receptor causes conformational
changes in variable loops 1, 2 and repositioning of variable loop 3. Additionally, the
binding of gp120 to the CD4 receptor causes the formation of a bridging sheet, which
comprises of two double-stranded β sheets. Together with bridging sheets and changes
in variable loop three aids in co-receptor binding (21). Variable loop 3 of gp120 binds to
coreceptor CCR5 and CXCR4, which further leads to fusion of the virus with the host
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Figure 1: The Life Cycle of HIV-1 (Adapted from Ronaldson et al., Glia, 56 (16), 1711-1735, DOI: 10.1002/glia.20725)
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cell membrane. In the brain, endothelial cells at the blood-brain barrier, astrocytes, and
oligodendrocytes can be infected with HIV-1 in CD4 independent fashion, using the
coreceptor (22).
Step 3: Fusion
Coreceptor binding exposes hydrophobic fusion peptide gp41, which inserts into the host
cell membrane. Then, the fusion peptide gp41 from each trimer folds at the hinge region
bringing an amino-terminal helical region (HR-N) and a carboxy-terminal helical region
(HR-C) together to form a six-helix bundle (23). Formation of the six-helix bundle is the
driving force in bringing the two membranes close to each other and resulting in pore
formation. With the formation of the fusion pore, viral contents are released into the host
cell cytoplasm. FDA approved fusion inhibitors, such as enfuvirtide, are peptides
designed on the C-terminus sequence of gp41, which mimic the HR-C domain of gp41,
and can bind and disrupt the intramolecular viral protein interaction preventing viral fusion
with the host cell membrane (24).
Step 4: Reverse transcription
After viral entry and fusion, the viral capsid comprising of reverse transcriptase, integrase,
and viral genomic RNA, is released into the cytoplasm (25). Immediately in the cytoplasm,
there is the partial dissolution of the capsid, which releases HIV-1 RNA and the reverse
transcriptase. The reverse transcriptase along with RNase H (Reverse Transcription
complex) converts HIV-1 RNA into double-stranded DNA (26). This step processed by
reverse transcriptase is highly prone to error, giving rise to many of the HIV mutations
responsible for the drug resistance against reverse transcriptase inhibitors (26). After
18

completion of DNA synthesis, the reverse transcriptase complex matures into the preintegration complex, comprising of linear viral DNA and proteins needed for viral
integration in host DNA. This process is aided by the HIV-1 protein vpr encoded by vpr of
HIV-1 genome (27). Reverse transcriptase, RNase, and integrase are encoded by pol of
HIV-1 genome (28).
The nucleoside reverse transcriptase inhibitor (NRTI) class of drugs competitively inhibits
reverse transcriptase by getting incorporated in the growing chain of viral DNA. This class
of drugs lacks 3’ OH group, which is required for elongation of viral DNA, thus terminating
viral DNA synthesis. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) acts at the
allosteric site of the reverse transcriptase and brings conformational change in the
catalytic site which prevents substrate attachment resulting in inhibition of the enzyme
(25).
Step 5: Integration
After completion of viral DNA synthesis, viral DNA along with viral and cellular proteins
required for integration are transported into the nucleus of the CD4 target cell. Inside the
nucleus, two nucleotides are removed for 3’ end of the viral DNA creating sticky ends,
which are integrated into the host genome. This process is catalyzed by the enzyme DNA
integrase (28). Lastly, ligation of viral DNA into host DNA takes place to give a single DNA
molecule (28). Integrase inhibitors, such as dolutegravir, raltegravir, and elvitegravir, act
at this step of the viral life cycle by non-competitively inhibiting DNA strand transfer activity
of integrase enzyme (25).
Step 6a and 6b: Transcription & Translation
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After the integration of viral DNA into the host genome, viral genes are expressed in the
host cell through transcription which initiates from a U3 promoter within the upstream
Long Terminal Repeat (LTR) (29). This step requires HIV-1 Tat for efficient elongation
(29). HIV-1 Tat is encoded by the HIV-1 tat gene. HIV-1 Rev, encoded by rev, and is
responsible for nuclear transport of unspliced mRNA, whereas smaller transcripts are
transported without the help of the Rev protein (25). This mRNA undergoes translation
using host cell machinery to produce the viral structural, enzymatic and regulatory
polyprotein precursors of Gag and Gag-pol (30). Structural proteins like viral capsid,
matrix and nucleocapsid are synthesized as precursor polypeptide Gag from HIV-1 viral
gene gag (25).
Step 7: Assembly and Budding
Both, Gag and Gag-pol precursor proteins multimerize through interactions of different
domains along Gag and are targeted by N- terminal myritic acid to the inner leaflet of the
plasma membrane (30). This allows Gag to preferentially associate at the plasma
membrane, where they concentrate in lipid rafts that potentially serve as assembly
platforms (31). At the same time, viral envelope proteins and viral genomic RNA are
recruited at the plasma membrane. In this step, the HIV-1 protease cleaves viral proteins
into smaller units, which assembles to form a mature virus that is now ready to infect other
cells (31). Accumulation of 1500 to 2000 viral polyproteins beneath the plasma membrane
induces curvature, leading to the formation of membrane coated spherical particles still
attached to the plasma membrane. HIV-1 p6, which is part of Gag, is responsible for the
final release of virus from the membrane by recruiting cellular Tsg101 protein and various
associated factors that belong to the vesicular sorting pathway (31).
20

Steps 8 and 9: Release and Maturation of viral particles
The virus particles released in the previous step have immature morphology,
characterized by a thin layer of circularly arranged Gag and Gag-Pol precursor
polyproteins. HIV-1 viral protease cleaves these precursor polyproteins into their
subcomponent. Due to this virus having characteristic conical inner cores are formed;
ready to attack other cells (31). HIV protease inhibitors (atazanavir, lopinavir, ritonavir,
darunavir)) competitively bind to HIV-1 protease and inhibits protease activity. HIV -1
protease is responsible for the cleavage of viral Gag and Gag-Pol precursors during viral
maturation (25).
Clinical Stages of Infection
In the absence of antiretroviral therapy, HIV progress into three clinical stages (32) (Table
1) :
Stage 1: Acute HIV Infection – It is characterized by flu-like illness lasting for a few weeks.
It typically occurs during the first 2-4 weeks of HIV infection. Infected individuals have
high viral titers during this phase, making them at higher risk of transmitting the virus.
Stage 2: Clinical Latency – In this phase, patients remain asymptomatic and viral
replication rates are very low. In the absence of antiretroviral therapy, patients can remain
in this phase for decades or can progress through it rapidly. At the end of this stage, viral
loads rapidly multiply, and CD4 cell counts decline, resulting in immunodeficiency if left
untreated.
21

Stage 3: Acquired Immunodeficiency Syndrome (AIDS) – It is the most severe form of
illness defined by a marked reduction in CD4 cell count ( < 200 cells/mm) and resulting
in much opportunistic illness. Lymph glands, chills, fever. Without the intervention of
antiretroviral therapy survival rates are around three years.
Table 1: Stages of HIV-1 infection
Stages of HIV-1

CD4 counts

Symptoms

≥ 500 cells/µL

Acute HIV-1 infection

infection
Stage -1

and persistent
generalized
lymphadenopathy (PGL)
Stage - 2

200 – 499 cells/µL

Mostly asymptomatic for
several decades if on
cART.

Stage - 3

≤ 200 cells/µL

Opportunitistic infections
and rare malignancies

Combination Antiretroviral Therapy
Zidovudine (AZT) is azidothymidine, nucleoside reverse transcriptase inhibitor, was first
introduced as a treatment for HIV 1987 and proved to be beneficial o HIV patients.
22

Treatment with AZT was able to reduce mortality and opportunistic infections in AIDS
patients by 8 to 24 weeks in an observational study (33). However, despite the early
successes, therapy with AZT was marred with severe toxicities, such as bone marrow
suppression, myalgia, and macrocytosis (33).

In the mid-1990s, several other

antiretroviral drugs were approved, which significantly improved the health outcomes of
people living with HIV, transforming HIV it from an acute, fatal disease to more of a chronic
condition (34). With the advent of combination antiretroviral therapy regimen (cART),
survival rates for individuals infected with HIV have increased to near normal lifespan in
comparison to 11 months in a pre-cART era (35, 36).
Based on the mechanism of action, antiretroviral drugs are classified in the following
categories (Table 2):
1) Nucleoside Reverse Transcriptase Inhibitors (NRTIs): NRTIs are phosphorylated
by host cellular kinases, and they compete with endogenous nucleosides to get
incorporated in growing chain of DNA. Once incorporated, NRTIs act as chain
terminators by blocking the production of proviral DNA.
2) Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs): NNRTIs bind to the
allosteric site of HIV-1 reverse transcriptase enzyme and form a hydrophobic
pocket proximal to the active site resulting in reduced activity of the enzyme.
3) Protease Inhibitors (PIs): Protease inhibitors inhibit the action of HIV-1 protease,
an enzyme which cleaves Gag and Gag-pol polyprotein precursor in the HIV-1
viral genome to generate matured active proteins.
4) Integrase Strand Transfer Inhibitors (INSTIs or Integrase Inhibitors): Integrase
strand transfer inhibitors block the strand transfer step, which is required for the
23

integration of viral DNA into host cellular DNA. Integrase Inhibitors sequester
magnesium cofactor ions of the enzyme and inhibits its activity.
5) Fusion Inhibitors: They are peptides which mimic HIV-1 fusion protein and prevent
binding of HIV-1 to host cell. Enfurvitide mimics HIV-1 glycoprotein 41 (gp41).
6) CCR5 Antagonists: CCR5 Antagonist blocks the CCR5 coreceptor on the surface
of host cells and prevents HIV entry into the cells.
7) Post Attachment Inhibitors: It is a monoclonal antibody which binds to the CD4 coreceptor on host cells and prevents attachment and entry of HIV into the cell.
8) Pharmacokinetic enhancers: They are used in treatment regimen to increase the
effectiveness of drugs and improve pharmacokinetic properties.

The integrase strand transfer inhibitor based cART regimen recommended by HIV/AIDS
guidelines, comprising of two nucleoside reverse transcriptase inhibitors (tenofovir,
emtricitabine) and an integrase strand transfer inhibitor (dolutegravir) were used in this
study (Table 3).

Table 2: HIV medicines based on drug classes
Class of Drugs

HIV Medicines

24

NRTIs

Abacavir, didanosine, emtricitabine,
tenofovir (Nucleotide), tenofovir
disoproxil fumarate (Nucleotide),
tenofovir alfenamide (Nucleotide),
lamivudine, zidovudine

NNRTIs

Efavirenz, etravirine, nevirapine,
elvitegravir

PIs

Atazanavir, darunavir, fosampenavir,
ritonavir, squinavir, tipranavir

INSTIs

Dolutegravir, Raltegravir, elvitegravir

Fusion inhibitors

Enfurvitide

CCR5 Antagonist

Maraviroc

Post- attachment inhibitors

Ibalizumab

Pharmacokinetic Enhancers

Cobicistat, Ritonavir

NRTI – Nucleoside reverse transcriptase inhibitor, NNRTI – Non-nucleoside Reverse
transcriptase inhibitor, PIs – Protease inhibitors, INSTI – Integrase Strand Transfer
Inhibitors
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Table 3: Antiretroviral drugs to be examined in this study
Drugs

Class

Protein Binding

Drug Transporter
Involvement

NtRTI

Molecular
Weight
(g/mol)
287.216

Tenofovir

Low, 7%

Emtricitabine

NRTI

247.248

Low, <4%

Dolutegravir

INSTI

419.385

High, >99%
bound to albumin

MRP4 Substrate
[36]
OAT1&3 Substrate
[37]
MATE1 Substrate
[38] MRP1
substrate (40) and
Inhibitor
MRP2 & MRP3
Inhibitor
P-gp inhibitor
(1mM)
CNT1,
ENT2 [36, 37]
Substrate
BCRP and P-gp,
OCT-2 Substrate
[41]

MRP- Multidrug Resistance Associated Protein, MATE- Multidrug and Toxin Extursion
Protein, P-gp – P-glycoprotein, CNT- Concentrative Nuceloside Transporter, ENTEquilibrative Nucleoside transporter, BCRP- Breast Cancer Resistance Protein, OCTOrganic Cation Transporter.
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HIV-1 Structure and Proteins

The mature HIV-1 particle is about 100 nm in diameter. It consists of the outer lipid bilayer membrane called the envelope, which contains surface proteins (gp120) and
transmembrane protein (gp41) product of the Env gene of the viral genome (34).
Envelope proteins are responsible for the interaction with the CD4 receptor, which then
results in viral entry into the host cell (23).
The inner surface of the viral membrane comprises of matrix shell has about 2000 copies
of matrix protein (MA, p17). Conical capsid core found at the center of the virus has about
2000 copies of capsid protein (CA, p24). There are two copies of identical viral genomic
RNA packed inside the capsid, which is stabilized by nucleocapsid (NA, p7) (35). These
proteins (MA, CA, NA) are the cleavage products of p55, which is encoded by the Gag
gene of the viral genome (35). Viral enzymes like reverse transcriptase, integrase, RNase
H are found along with the viral RNA inside the capsid, which are encoded by the Pol
HIV-1 gene (36).
HIV-1 has other regulatory proteins like Vif, Nef, Vpr that are packaged inside the virus
particle. Alternatively, Tat, Rev, and Vpu proteins are not packaged inside the virus
particle. Instead, they are synthesized inside the host cell (37). This work will focus mostly
on HIV-1 Tat. Information of about other proteins is elaborately covered in the review by
Faust et al. (38).
HIV-1 Tat
HIV-1 Tat (Transactivator of transcription), is a 14 kDa protein. Tat is also one of the first
viral proteins to be synthesized by the host cell during the infection (43). After the
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integration of viral DNA into the host genome, RNA II polymerase is recruited to the
promoter region (5’ long terminal repeat) to start the transcription (25). Although several
host transcription factors like NF-KB can bind to this region and increase viral gene
expression, they mostly produce incomplete and short viral transcripts (44). To
circumvent this, HIV-1 produces its transcription factor (HIV-1 Tat) to increase the fidelity
of RNA II polymerase (45, 46).
HIV-1 Tat is an RNA binding transcription factor, which binds to TAR (Transactivator
response element) located on viral RNA. After binding, it recruits host positive
transcription elongation factor-b (p-TEFb) at the loop of 5` end of viral RNA (47). Tat-PTEFb complex phosphorylates RNA II polymerase resulting in expression of viral genome
and post-integration events like maturation (48). P-TEFb consists of cdk-9 and cyclin T1
(Cyclin T1) subunits. In its inactive form, P-TEFb binds to 7SK snRNP (small nuclear
Ribonuclear Proteins), where HEXIM1 (Hexamethylene bis-acetamide-inducible protein1) protein inhibits the kinase activity of cdk-9. HIV-1 Tat competes with HEXIM1 for
binding at this site, and in doing so releases p-TEFb from 7SK snRNP toe recruited at
viral promoter for activation of RNA II polymerase (49).
HIV-1 Tat also alters the expression of cellular genes to promote viral replication. It
induces transcription and secretion of chemokines (CXCL-10, CCL-2, CCL-3) in immature
dendritic cells, resulting in recruitment of T-cell and monocytes (50). These events could
amplify viral replication as these migrated cells can be further infected by HIV-1. Tat can
bind to cellular promoters and increase expression of regulatory proteins like PP2A
phosphatase leading to activation of proapoptotic pathways (51). HIV-1 Tat secreted
extracellularly during infection can enter other cells through endocytosis (52).
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Extracellular Tat has been implicated in various AIDS pathologies. For instance,
extracellular Tat induces neovascularization responsible for tumor growth and metastasis
in hypervascularized Kaposi’s sarcoma (53). HIV-1 Tat transactivates the genome of
herpes virus, hepatitis C virus, and human Cytomegalovirus, facilitating opportunistic
infections during AIDS (54–56). Lastly, HIV-1 Tat is neuro-inflammatory and plays a vital
role in the neuropathogenesis of HIV-associated neurocognitive disorder (HAND) (57,
58). This document will mostly focus on the effects of HIV-1 about HAND.
HIV-Associated Neurocognitive Disorder

Approximately, 60% of individuals infected with HIV suffer from HIV associated
neurocognitive disorder (HAND), which is a spectrum of neurocognitive impairment
ranging from asymptomatic neurocognitive impairment to full-blown dementia (59).
Despite aggressive use of combination antiretroviral therapy (cART), HIV viral loads
persist in the central nervous system (CNS) (as measured in cerebrospinal fluid (CSF))
and the prevalence of mild to moderate neurocognitive impairment continues even after
ten years of suppressive therapy (60). Based on severity, the HAND is classified into three
groups: asymptomatic neurocognitive impairment (ANI), mild neurocognitive disorder
(MND) and HIV-associated dementia (HAD). In a post-cART era, asymptomatic to a mild
form of the HAND are prevalent while the severe form (HAD) is rarely seen (61).
HIV- 1 enters the brain soon after the infection (62, 63). It can either cross the blood-brain
barrier (BBB) through transcytosis or through the “Trojan Horse” approach, where virusinfected immune cells migrate through BBB. Once inside the brain, virus sheds off from
the immune cells principally monocyte-derived macrophages (MDMs), releases viral
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proteins, and infects other cells in the brain (64, 65). In doing so, several chemokines and
cytokines are released, which further increases the flux of immune cells into the brain
through chemotaxis which results in the amplification of the infection (66). Inside the brain,
HIV can infect many cell types like brain microvascular endothelial cells, glial cells
(astrocytes, microglia), perivascular macrophages, and pericytes. There is scant
evidence supporting HIV infection in neurons. Neurons lack CD+4 receptors but do
express CCR5, CXCR4, CCR3 receptor required for HIV-1 infection. HIV-1 predominantly
replicates in microglia and perivascular macrophages in CNS, while it infects other cells,
but there is little or no replication (22). The infected cells secrete inflammatory cytokines
and chemokines, which can contribute to neuronal injury and eventually neuronal death.
There are two hypotheses regarding neuronal injury/death during HIV infection: (1) the
direct injury hypothesis; HIV-1 Viral proteins like gp120, Tat, Vpr which are secreted
during the infection are neurotoxic and that leads to neuronal injury and (2) the bystander
effect hypothesis; which proposes neuronal injury/death are due to neuroinflammation
caused by CNS infected cells (66, 67). Infected microglia and astrocytes release
monocyte chemoattractant protein -1 (MCP-1, MCL-5, RANTES, CCL2), which is
responsible for chemotaxis of MDMs into the brain via BBB (68). These MDMs can bring
more virus inside CNS through Trojan horse approach and release viral proteins causing
sustained inflammation in CNS. Microglia and astrocytes activated via feedback loop can
further increase secretion of inflammatory from these
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Figure 2: HIV-1 in the brain
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cells. All these factors eventually contribute to neuronal injury or neuronal death (Figure
2).
This dissertation will focus on the effects of the HIV-1 Tat protein and drugs of abuse in
different CNS cell types known to have an important role in the neuropathogenesis related
to the development of HAND. The cell types used in this dissertation are brain
microvascular endothelial cells, astrocytes, microglia, and pericytes.
Human Brain Microvascular Endothelial cells

Brain microvascular endothelial cells constitute the lining of the brain vasculature, which
represents BBB. The blood-brain barrier forms the physical, metabolic and transport
barrier between systemic circulation and CNS (69). The BBB is characterized by tight
junction proteins (Claudin-5, Occludin, Junctional Adhesion molecules) which are
responsible for the barrier properties of the BBB (67). These proteins are connected to
the actin cytoskeleton via cytoplasmic proteins like zonula occludens -1, 2, 3 (ZO-1, 2,
and 3). Tight junction proteins act as glue between endothelial cells in brain microvessels.
The passage of ions through BBB is restricted by tight-junction proteins, creating an ionic
barrier which is vital for neural transmission and maintaining brain microenvironment (67).
This charge barrier is measured as, Transendothelial electrical resistance (TEER), which
experimentally indicates the integrity of monolayer of endothelial cells (70). BBB also
contains γ-glutamyl transpeptidase (γ-GTP), alkaline phosphatase (AP), and aromatic
acid decarboxylase responsible for the metabolism of several drugs. Additionally, there
are multiple transporters located on the luminal and abluminal side responsible for the
influx or efflux of cargo, thereby having a precisely regulated system of permeability. This
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selective permeability of solutes and ions helps maintain the ionic environment for the
transduction of electrical signals in neurons.
Effect of HIV-1 Tat on brain microvascular endothelial cells
HIV-1 Tat enters the cell through absorptive endocytosis (43). Radio-labeled HIV-1 Tat
injected intravenously in the mouse was found to be maximally distributed in the
hippocampus, occipital cortex, and hypothalamus inside the brain, which is in congruence
with HAND pathology observed in those parts of the brain in the Tat transgenic mouse
model and post-mortem brain samples from HAND patients (71, 72). HIV-1 Tat is reported
to decrease expression of tight junction proteins (claudin-5, occludin, and ZO-1) by upregulating MMP-2 and 9, increased monocyte migration mediated via Rho activation (73),
increased expression proinflammatory cytokines IL-6, IL-10, and TNF-α (74). Tat
activates NF-κB and mitogen-activated phosphorylate kinase pathways leading to
accumulation of TNF-α, which further up-regulates matrix metalloproteinase-9 (MMP-9)
levels. Elevated levels of MMP-9 disrupts laminin and type IV collagen in brain
microvasculature leading to increased permeability (75). HIV-1 Tat causes oxidative
stress by releasing reactive oxygen species, which is amplified with TNF-α (76). HIV-1
Tat is also reported to increase expression of ABC family (P-glycoprotein) of transporters
through a multitude of signaling pathways, which results in increased extrusion of
antiretroviral drugs outside the brain (77–79)
Human Astrocytes
Astrocytes are derived from neuro-ectoderm embryonic lineage. Astrocytes provide a vital
role in support of neurons and glial transmission (80). Potassium ions are released into
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the extracellular space during neuronal activity, increasing the concentration of potassium
(K+) ions and resulting in depolarization of neuronal membrane affecting axonal
conduction and synaptic transmission. Astrocytes clear these potassium ions through
potassium channels (Kir4.1) (81, 82). Astrocytes are responsible for the maintenance of
the blood-brain barrier by secreting growth factor-like Vascular endothelial growth factor
(VEGF), glial -derived neurotrophic factor (GNDF), and basic fibroblast growth factors
(83). These factors promote the formation of tight junctions, the polarization of
transporters, and inducing enzymes at the BBB (83).
Effect of HIV-1 Tat on astrocytes
One of the hallmarks of the pathology of HAND is astrocytosis, which is characterized by
hypertrophy of astrocytes and increased expression of the glial fibrillary acidic protein
(84). HIV-1 virus and viral proteins (HIV-1 Tat, gp-120) released due to HIV infection are
responsible for astrocytosis. HIV-1 Tat is a potent activator of NF-κβ, it increases
production of MCP-1 (CCL2), IL-6, and TNF-α in astrocytes via NF-κβ signaling pathway
(85). Higher levels of MCP-1 are correlated with neurocognitive deficits due to HIV-1
infection (86). HIV-1 Tat also causes oxidative stress in astrocytes by releasing reactive
oxygen species causing increased expression of adhesion molecules like VCAM-1/ICAM1 in endothelial cells (83). Up-regulation of adhesion molecules leads to increases
adhesion of monocyte-derived macrophages, leading to disruption of BBB.
Glutamate is a predominantly excitatory neurotransmitter in the brain. Removal of
glutamate from the extracellular fluid is vital for the normal functioning of neurons.
Glutamate is cleared mostly by neurons and astrocytes; however, it is reported that
glutamate transporters on astrocytes are responsible for 90% of glutamate clearance
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(87). In vitro studies have demonstrated a reduction in the glutamate transporter (EAAT1,2) in astrocytes in response to exposure to HIV-1, gp-120 and HIV-1 Tat (88, 89).
Excitotoxic damage to neurons in HIV-1 infection is mediated by activation of the NMDA
receptor by glutamate resulting in the intracellular accumulation of calcium ions (87).
Astrocytes respond robustly to viral proteins (HIV-1 Tat, gp120) and release inflammatory
cytokines (glutamate, ROS, TNF-α, IFN-γ, and IL-6), which cause neuronal injury or
death. Astrocytes are also considered to be latently infected with HIV, which makes CNS
a reservoir of HIV (90). This dysregulation in astrocytes contributes significantly to the
neuropathogenesis of HAND.
Human Microglia

Microglia are the site for productive replication of HIV in CNS.

They are resident

macrophages of the CNS derived from mesoderm (43). Perivascular macrophages seed
the initial HIV-1 infection in CNS near the brain microvasculature, and the virus is
transmitted through parenchyma towards microglia (22). Typically, microglia appear
either in the resting or active state. The resting versus the active state of microglia can be
differentiated by their morphology; cells are rounded in an active state and ramified in
resting state (22). Activated microglia are absent in adult life but can be seen in
developing the brain, or inflammatory conditions, such as HAND, within fully developed
CNS (22). Infected microglia can release the virus, viral proteins (gp-120, tat, vpr),
inflammatory cytokines (TNF-α, Platelet-activating factor (PAF), IL-1β), which can further
activate uninfected microglia/astrocyte through positive feedback loop or can be directly
neurotoxic (92). Despite microglia being a major site of productive replication, much of
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the sustained inflammation, contributing to neurotoxicity is due to the response elicited by
uninfected microglia (90). Even in patients with undetectable viral loads in their plasma,
sustained inflammation is observed in microglia. This is a potential explanation for the
prevalence of mild and asymptomatic forms of HAND even during suppressive
antiretroviral therapy (92).
Effects of HIV-1 Tat on microglia
HIV-1 Tat induces expression of pro-inflammatory cytokines (TNF-α, IL-1β, IFN-γ, and IL6) via NF-KB signaling pathway (93). These cytokines can further activate astrocytes
through a positive feedback loop or are directly neurotoxic. Additionally, HIV-1 Tat causes
secretion MCP-1(CCL2), IL-8, IP-10, MIP-1α, MIP-1β and RANTES (CCL5) in human
microglia, which can lead to chemotaxis of monocytes and leucocytes inside the brain
(94). Overall, this milieu of inflammatory cytokines causes prolonged inflammation in CNS
resulting in excitotoxic damage to neurons.
Human Pericytes

Pericytes are flat, undifferentiated, contractile cells that wrap around the basal lamina of
the microvasculature (95). In an in-vitro study, it was demonstrated that co-culture of
human pericytes with brain microvascular endothelial cells results in polarization of
endothelial cells, suggested by proper localization of P-glycoprotein (96). Furthermore,
studies in adult pericyte deficient mouse showed increased permeability to water and lowhigh molecular weight tracers. Pericytes maintain BBB by regulating expression of BBB
specific genes and inducing polarization of astrocytic end-feet via PDGFRB activation
(97). Additionally, in a study from the brains from HIV-infected patients as compared to
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uninfected brain tissue, pericyte markers like α1-integrin, α1- smooth muscle actin were
significantly reduced in HIV, even for those patients that had been on antiretroviral
therapy, suggesting that HIV infection results in the loss of pericyte coverage irrespective
of antiretroviral therapy (98). Upon exposure to TNF-α and IL-1β, upregulation of
adhesion molecules was observed, which resulted in increased adhesion of monocytes.
Pericyte inclusion into an in-vitro BBB model with endothelial cells resulted in enhance
monocyte migration as compared to the endothelial cell-only BBB model. (98) .
Effects of HIV-1 Tat on Pericytes
HIV-1 Tat induces MAPK (Erk and JNK) pathways, which lead to nuclear localization of
NF-κB and induction of PDGF-BB. Elevated levels of PDGF-BB results in loss of integrity
of BBB due to movement of pericytes away from microvasculature (99).
Drug Abuse and HAND

Drug abuse and HIV are interlinked epidemics. Injection drug users are nine times at
higher risk of getting HIV. Not only does substance abuse increases the risk of
transmission, but it intrinsically alters neuropathogenesis of HIV. There is substantial
evidence from laboratory-based and epidemiological studies suggesting drugs of abuse
can exacerbate disease progression in HIV and also affects mortality and morbidity of
HIV patients. This document will investigate the effects of drugs of abuse
(methamphetamine and morphine) in brain endothelial cells, astrocytes, pericytes and
microglia.
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Methamphetamine

Methamphetamine is the second most abused drug in the world (100). Its co-exposure is
frequently seen in HIV-infected patients, perhaps, due to risky sexual behavior caused
under its influence and sometimes when injected through needles (101). Cognitive
impairment caused by methamphetamine can lead non-adherence to medications
worsening symptoms of HAND (102). Methamphetamine can enhance replication of HIV1 by activating the promoter in microglia; an effect that can be synergized with HIV-1 Tat
(103). It also causes disruption of blood-brain barrier by oxidative stress, excitotoxic
damage by glutamate and release of inflammatory cytokines (104). The release of
inflammatory cytokines by activated glia after methamphetamine exposure is linked to
behavioral deficits in HAND (105). Methamphetamine effects on the BBB can be variable
and often transient. There are several reports of methamphetamine exposure resulting in
tight junction protein alterations, enhanced BBB permeability, diminished barrier
tightness, and increased monocyte migration across the BBB (106, 107). However, other
investigators have reported either no effects or transient effects on TEER, tight junction
protein expression, and on paracellular permeability (108–111). We hypothesize that
Meth alone or with HIV-1 Tat disrupts the BBB and alters antiretroviral penetration inside
the brain.
Morphine

Morphine is an alkaloid obtained from seeds of the poppy, papaver somniferum. It exerts
its pharmacological action of alleviating pain by acting as an agonist of µ-receptor.
Activation of µ-receptor by morphine leads to closing of voltage-gated calcium channels,
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stimulation of potassium efflux, and decrease the production of cAMP due to inhibition of
adenylyl cyclase (112). Collectively, these events lead to decreased neuronal
transmission and inhibition of neurotransmitter release (112). Morphine also regulates
dopamine within nucleus accumbens predisposing it to abuse liability. A majority of action
by morphine is exerted through µ-receptor, and to a lesser extent by κ or δ- opioid receptor
(112). Despite having sufficient lipophilicity, morphine has a relatively low uptake into the
brain (113). This low uptake of morphine can be explained by it being a substrate of Pglycoprotein (P-gp) located at the luminal side of the BBB (114). Expression of P-gp at
BBB has been observed to alter during inflammation and other pathological conditions,
which directly affects morphine uptake into the brain (114).
Injection drug users of opiates (morphine) have an increased risk of transmission of HIV.
It is also reported that opiates fasten disease progression and exacerbate neuropathology
in SIV models (115). Clinical studies in the post-cART era have found that HIV-1 infected
individuals who abuse heroin (an acetylated derivative of morphine) showed significant
neurocognitive deficits especially poor working memory and recall (116). These deficits
persisted even after abstinence from heroin for long periods. Initially, morphine increases
efflux of inwardly rectifying potassium current making neuron less excitable, however,
from chronic exposure and tolerance neurons are decoupled from inwardly rectifying
current resulting in increased excitability (113). Morphine provokes pronounced and
robust inflammatory response in glia of HIV-1 infected individuals, especially astroglia.
This response is spiraled by positive feedbacks loops formed between astrocytes and
microglia resulting in sustained cytokine production (117). Overall, interactive effects of
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prolonged inflammation by opiates on top of already existing inflammation due to HIV-1
infections leads to neurotoxicity exacerbating HAND.
Effects of morphine on brain microvascular endothelial cells
Brain microvascular endothelial cells express µ and opioid-related nociceptive opioid
receptors. Endogenous opioids play an essential role in vascular development and
differentiation (118). Activation of κ- opioid receptors are implicated in reduced vessel
growth and differentiation, morphine being a mixed µ/κ opioid receptor agonist is likely to
affect vessel growth and differentiation of endothelial progenitor cells (118). Mahajan et
al. reported that treatment of brain microvascular endothelial cells with morphine causing
reduction in TEER (119). TEER is a measure of blood-brain barrier integrity, as it
measures the flux of ions through the barrier. Additionally, treatment of brain
microvascular endothelial cells with HIV-1 Tat and morphine resulted further decrease in
TEER values, demonstrating the additive effect (119). Treatment with morphine showed
decreased expression of ZO-1 and occludin. However, the combined effects of Tat and
morphine were not statistically significant compared to morphine alone (119). Morphine
and Tat showed an additive effect on transmigration of PBMCs through BBB. These
results suggest that morphine causes an increase in blood-brain barrier permeability,
which is exacerbated by HIV-1 Tat (119). Clinically, it means more virus can invade the
brain due to increase permeability resulting in worsening of HAND.
Morphine and Tat act synergistically to increase the production of inflammatory cytokines
(TNF-α, IL-8) and intracellular calcium (121). These events can lead to activation of
Myosin light chain kinases mediated by IP3 resulting in dysfunction of BBB and including
a leakier barrier (119).
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HIV-1 Tat and morphine were found to increase the expression of P-gp. P-gp is an efflux
transporter located on the luminal side of blood-brain barrier (119). Many antiretroviral
drugs are a substrate of P-gp, increased expression of P-gp results in more efflux of the
drug outside the brain, the worsening prognosis of HAND.
Effect of morphine on astrocytes
Astrocytes express µ, κ, δ opioid receptors (120). Also, they have undeniable significance
in neuronal support and glial transmission (118). There are reports of differential
expression of opioid receptors on astrocytes on the basis of the cell cycle and
development stages. There is also a regional difference in the expression of opioid
receptors in astrocytes located in different parts of the brain (121). Overall, δ and κ opioid
receptors are expressed at a much higher level than µ opioid receptor from astrocytes
isolated from all parts of the brain (122). Cortical astrocytes had the highest level of total
opioid receptors based on mRNA expression, as well as µ receptor expression (122).
Opiates drugs act by disrupting the ion and neurotransmitter homeostasis maintained by
astrocytes in extracellular space, thereby causing neuronal injury and death. Opioids
cause increases in intracellular concentration of calcium in astrocytes mediated IP3
pathway, which is synergistically increased by HIV-1 Tat, resulting in increased
production of CCL2, CCL5, IL-6, and TNF-α. HIV-1 Tat and morphine cause increased
production of RANTES and MCP-1 resulting in recruitment and activation of microglia and
sustained inflammation (83). Morphine causes decrease expression of glutamate uptake
transporter EAAT1 and EAAT2, affecting glutamate buffering capacity of astrocytes, in
turn causing excitotoxic damage to neurons (118). HIV-1 Tat ± morphine can increase
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replication of HIV, increased cytokine release and causes neurotoxicity. In a nutshell,
morphine exacerbates neuropathogenesis of HAND in astrocytes.
Effect of morphine on Microglia
Microglia express µ, κ, δ opioids receptors. Microglia are one of the major sites for
productive replication of the virus in CNS. Morphine has shown to cause microglial
recruitment and activation (123). Morphine provokes major pathological events regarding
HAND in microglia like an increase in inflammatory cytokine release, increase in oxidative
stress, disruption of intracellular calcium homeostasis, and increased trafficking of
monocyte-derived macrophages (124). Morphine is found to induce expression of CCR5
and CXCR4 receptors on microglia, which maybe partly due to secretion of chemokines
(TNF-α, IL-2) that induces expression of chemokine receptor or decrease the production
of chemokines which internalize these receptors in microglia (125). Collectively, morphine
exacerbates the dysregulation of microglial functions, in an already compromised state
due to productive infection of HIV-1.
Effect of morphine on pericytes
There were very few studies in current literature studying the effects of morphine on
pericytes associated with brain micro-vessels. In an in-vitro study, morphine causes
MAPK/ERK-mediated phosphorylation in pericytes mediated by the release of plateletderived growth factor-BB from human umbilical vein endothelial cells, resulting in
promotion of tumor angiogenesis and impairment of antiangiogenic therapy (122). It
remains to be investigated the role of morphine in HIV-1 infected pericytes. Being a critical
mediator for development and maintenance of blood-brain barrier, any inflammatory
response from pericytes will have a reverberating response to the already disrupted BBB.
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Antiretroviral penetration into the brain

The BBB limits antiretroviral drug penetration into the brain by acting as a physical
impediment to the transport of drugs in CNS. It also possesses several efflux and uptake
transporters, which are responsible for restricting antiretroviral drugs in the brain (Table
3). Once inside the brain, drug penetration into different CNS cells is further reduced by
these transporters. This reduced penetration of antiretroviral drugs had caused the subtherapeutic concentration of drugs in the brain leading to low-grade viral replication, CNS
compartmentalization of the virus, drug resistance and irreversible CNS damage (126).
CNS penetration effectiveness (CPE) score measures drug penetration inside the brain;
higher scores indicates more penetration in the brain (127). There had been a reduction
in HIV RNA in CSF with the drug with higher CPE scores (61). Besides that, the utility of
CSF as a surrogate marker for CNS drug exposure remains controversial. CSF drug
concentration indicates the extracellular availability of the drug in the brain; however, it
does not divulge information on intracellular drug concentration in brain parenchyma
(128). In addition to that, there had been an inconsistent relationship between higher CPE
score and clinical outcomes of HAND (61). There is a varying degree of efficacy of
antiretroviral drugs in different cell types. For instance, NRTI's requires lower EC 50 in
macrophages than lymphocytes due to low levels of endogenous nucleoside pool in
macrophages compared to lymphocytes, which causes lower competition between drug
and nucleoside in macrophages than in lymphocytes indicates differential efficacy of
antiretroviral drugs (131, 132). Gray et al., showed EC90 for NRTIs (Lamivudine,
Stavudine, and Zidovudine) was many times higher than the achievable concentrations
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in CSF (131). These results warrant a thorough investigation into antiretroviral drug
penetration in different brain cell types and brain regions.

Table 3: Transporters expressed on cell type of interest
Cell Type

Efflux Transporter Expressed

hCMEC/D3 & HBMEC

P-gp, MRP-1,2,4,5 and BCRP(132),
MATE (low level in hCMEC/D3)(133)
MATE is not present in HBMEC(134)

Human Astrocytes

P-gp(135),(136), MRP-1, 4, 5(137),
BCRP(138),(139), OCT-3 (140)

Human Pericytes

P-gp(135)

Human Microglia

P-gp(141), MRP-1(142)

hCMEC/D3- human Cerebral Microvascular Endothelial cells /D3, HBMEC- Human Brain
Microvascular Endothelial Cells, P-gp – P-glycoprotein, MRP-1, 2, 4, 5 – Multidrug
Resistant Protein 1, 2, 4, 5, BCRP-Breast Cancer Resistant Protein, OAT- Organic Anion
Transporter, OCT – Organic Cation Transporter.
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Effects of HIV-1 Tat and Methamphetamine on Blood-Brain
Barrier Integrity and Function In Vitro
Patel, Sulay et al. “Effects of HIV-1 Tat and Methamphetamine on Blood-Brain Barrier Integrity and
Function In Vitro.” Antimicrobial Agents and Chemotherapy61.12 (2017): e01307–17. PMC. Web. 7 July
2018.

INTRODUCTION
Despite aggressive use of combination antiretroviral therapy (cART), HIV infection results
in HIV-associated neurocognitive disorders (HAND) in about half of infected individuals
(143–148).

Neurocognitive

dysfunction

can

include

decreased

attention

and

concentration, as well as deficits in information processing, memory, learning, and
psychomotor speed. There may also be motor slowing, incoordination, and tremor (143,
149). Although the severity of the most severe form of HAND, HIV-associated dementia
(HAD), has diminished in the post-cART era, the incidence of HAND and accompanying
deficits in neurobehavioral function persist as HIV/AIDS evolves into a chronic disease
(147, 150).
The neurocognitive impairment seen in HIV type 1 (HIV-1)-infected individuals in the postcART era is thought to principally result from a loss in synaptic connectivity (150, 151).
The synaptodendritic injury is likely caused by the combined release of “cellular toxins”,
which includes excessive oxyradicals and increases in inflammatory cytokine and
chemokine secretion, and “virotoxins” consisting of neurotoxic viral proteins such as Tat
and gp120 (152, 153). HIV is thought to enter the brain through infected macrophages,
which traverse the vascular endothelium associated with the blood-brain barrier (BBB)
(74, 154), and take up residence within the perivascular space of the central nervous
system (CNS). The infected perivascular macrophages can subsequently infect resident
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microglia (155–157), as well as astroglia (158, 159). Limiting the bidirectional trafficking
of HIV-infected macrophages into the CNS and restricting HIV replication within CNS
compartments is of critical importance in restricting the viral production proteins and
limiting CNS inflammation that drives HAND (22, 160–162).
A key limitation in fighting HIV infection in the CNS results from the restricted penetration
of antiretroviral drugs across the BBB despite excellent systemic effectiveness. The BBB
is the primary barrier limiting the passage of substances from the blood into the brain. The
BBB is a selective barrier composed of microvascular endothelial cells lining the brain
microvessels. The endothelial cells are surrounded by a basal lamina, pericytes, and
astrocytic endfeet, which contribute to the induction and maintenance of BBB properties
(69, 163–167). The BBB has an active interface between the circulation and the CNS,
restricts the free movement of substances between blood and CNS, and is critical in
maintaining CNS homeostasis (168). This barrier function is maintained by two major
mechanisms. A paracellular barrier is formed by tight junctions between endothelial cells
and restricts movement of water-soluble compounds between adjacent cells. A
transcellular barrier is mediated by transcytosis involving the trafficking of specific
substances in endocytotic vesicles through endothelial cells and is also mediated by the
movement of specific substances by specific transporters. Endothelial cells express
various efflux transport proteins (such as P-glycoprotein (P-gp; gene symbol ABCB1),
breast cancer resistance protein (BCRP; gene symbol ABCG2), and multidrug resistance
proteins (MRPs; gene family symbol, ABCC family). These transporters limit CNS
exposure by active expulsion of substances from brain endothelial cell cytoplasm back
into the blood (168).
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Drug abuse exacerbates cognitive impairment and pathologic CNS changes in HIVinfected

persons.

Experimental

and

clinical

evidence

indicates

that

HIV

neuropathogenesis and neurocognitive deficits are exacerbated with co-exposure to
methamphetamine (169–172). Methamphetamine induces HIV transcription, potentiates
HIV viral protein-mediated oxidative stress pathways in the brain (173), and increases
pro-inflammatory cytokines (174).
Individually, HIV-1, HIV viral proteins, gp120 and Tat, and methamphetamine are known
to disrupt the BBB. Our lab has demonstrated increased leakiness of fluorescent tracer
compounds into the brain in Tat transgenic mice (175). In vitro, Tat and gp120 treatment
of endothelial cells results in decreases in several important tight junction proteins with
resultant increases in endothelial monolayer permeability (176). HIV-1 and the viral
proteins Tat and gp120 have complex and variable effects on drug efflux proteins within
cells of the neurovascular unit. In rodent brain microvascular endothelial cells, Tat induces
P-gp and Mrp1 expression and function in brain microvascular endothelial cells (78, 177,
178). However, in primary human astrocytes, HIV can downregulate P-gp expression
(179, 180). Methamphetamine effects on the BBB can be variable and often transient.
There are several reports of methamphetamine exposure resulting in tight junction protein
alterations, enhanced BBB permeability, diminished barrier tightness, and increased
monocyte migration across the BBB (106, 107). However, other investigators have
reported either no effects or transient effects on transendothelial electrical resistance
(TEER), tight junction protein expression, and on paracellular permeability (108–111). To
date, there is limited information regarding the effects of methamphetamine and Tat coexposure on the BBB. One study reports enhanced alterations in tight junction protein
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expression in the brain endothelium, a breakdown of BBB integrity as shown by
decreased TEER and enhanced monocyte migration upon co-exposure with Tat and
methamphetamine (106).
Although these limited studies provide some insight into how HIV-1 proteins and
methamphetamine can alter the integrity of the BBB, it is not known how the molecular
alterations in the BBB disrupt the function of the barrier. Specifically, it is uncertain the
extent to which HIV-1 protein and methamphetamine-induced alterations in cART
penetration result from disruptions to BBB integrity and/or drug transporter function. In
the current study, the effects of Tat and methamphetamine exposure on factors affecting
antiretroviral penetration, such as paracellular and transcellular barrier integrity and drug
transporter function, were investigated in an in vitro model of the BBB.
Methods
METHODS
Materials and Reagents
Ascorbic acid, DMSO, human basic fibroblast growth factor (bFGF), hydrocortisone,
lucifer yellow, Rhodamine 123 (Rh123), verapamil hydrochloride, were obtained from
Sigma Aldrich (Saint Louis, MO). Propranolol was purchased Fisher Scientific (Pittsburg,
PA). MK-571 was purchased from Cayman Chemical (Ann Arbor, Michigan). The
following reagents were obtained through the AIDS Reagent Program, Division of AIDS,
National Institute of Allergy and Infectious Disease (NIAID), National Institute of Health
(NIH): atazanavir and lopinavir. [3H]-atazanavir and [3H]- propranolol was purchased from
Moravek (Brea, CA). HIV-1 Tat1-86 was purchased from Immunodiagnostics, Inc (Woburn,
MA). Endothelial basal medium (EBM-2) was purchased from Lonza (Basel, Switzerland);
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Chemically defined lipid concentrate, penicillin-streptomycin, trypsin/EDTA, 4-(2hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) were obtained from Invitrogen
(Waltham, MA); fetal bovine serum (FBS) from PAA The Cell Culture Company
(Pasching, Austria); and Lithium chloride from Merck (Kenilworth, NJ).
Cells
hCMEC/D3 cells were grown in EBM-2 supplemented by Lonza’s EGM2-MV Bullet Kit
(Fisher, Waltham, MA, cat# NC9902887, which has 5% FBS plus growth factors.
Additional supplementation with 10 mM HEPES, 1X penicillin/streptomycin and 1 ng/mL
bFGF was also made, and this media was called growth media. After hCMEC/D3 were
plated on transwells, the cells were grown in EBM-2 media, supplemented with 5% FBS,
1× penicillin/streptomycin, 1 ng/mL hydrocortisone, 5 μg/mL ascorbic acid, 0.05%
chemically defined lipid concentrate, 10 mM HEPES, 1 ng/mL bFGF and 10 mM lithium
chloride (subsequently referred to as transwell medium). Cells were grown in transwell
media for 48 h, and then serum supplementation was decreased to 1.25% FBS.
Blood-Brain Barrier Model
Human brain microvascular endothelial cells, hCMEC/D3, were generously provided by
Dr. Babette Weksler of Weill Cornell Medical College, Cornell University (New York, NY).
This cell line was selected because it is well characterized, of cerebral origin, and is
derived from human brain microvascular endothelium (132, 181). These cells express
chemokine receptors, up-regulate adhesion molecules in response to inflammatory
cytokines, and display characteristics of the BBB, including tight junctional proteins and
the capacity to actively exclude drugs (181, 182).
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hCMEC/D3 cells, between passages 25 and 35, were maintained at 37°C with 5% CO2.
To generate the BBB model, cells were seeded at a density of 15 × 104 cells/well on the
upper surface (the apical chamber) of 12-well transwell plates. The base of each transwell
insert is configured with a polycarbonate membrane with 3.0 μm diameter pores (Corning,
Fisher Scientific, Pittsburgh, PA) pre-coated with rat-tail collagen type I (Cultrex). Medium
was replenished with fresh medium every other day for 4 days until functional studies
were performed. To assess the integrity of the BBB, TEER was measured on the transwell
membrane insert plates using EVOM2 chopsticks from World Precision Instruments
(Sarasota, FL). Preliminary data from our lab demonstrates that the hCMEC/D3 cells form
its tightest paracellular barrier by day 6 in vitro, as determined by TEER (Fig. 4A).
Treatment
The Tat concentration (100 nM) used in this study was based on published research (85,
124, 183–185) and is also within the range of concentrations detected in serum of HIVinfected individuals (186). A methamphetamine concentration of 10 µM was chosen
based on preliminary screening of different concentrations (0.01, 0.1, 1, and 10 µM). This
range was selected based on concentrations detected in the blood of methamphetamine
users (187).
Cell Viability
LIVE/DEAD Viability/Cytotoxicity Kit (Life Technologies, Waltham, MA) was used to
measure hCMEC/D3 viability when treated with Tat and methamphetamine. A working
solution of 2 μM ethidium homodimer-1 (EthD-1) and 1 μM calcein-AM was made in
DPBS. hCMEC/D3 cells were seeded on a sterile 24-well plate at 5 × 10

4

cells/mL.
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hCMEC/D3 cells were then treated with Tat and methamphetamine) for 24 h. 200 μL of
working solution was added to each well for 30 min at RT. Fluorescent images were taken
at excitation/emission wavelengths 495/515 nm to visualize calcein-AM (live cells) and
528/617 nm to visualize EthD-1 (dead cells). Ten images were taken at random for both
calcein-AM and EthD-1 and analyzed using ImageJ software (NIH). The relative ratio of
live/dead cells was quantified by evaluating the fluorescent pixels of green and red.
Substrate Permeability
Briefly, apical-to-basolateral flux (A-to-B; mimicking blood to brain flux across the BBB)
of the compound was conducted as follows. Cell monolayers were pre-incubated with
transport buffer (Hanks’ balanced salt solution (HBSS) with 25 mM D-glucose and ten
mM HEPES, pH 7.2) for 30 min at 37°C. The apical (donor) compartment buffer was
replaced with 0.5 mL of transport buffer containing substrate. The accumulation of the
compound in the receiver (basolateral) compartment was assessed at intervals up to 60
min. For basolateral-to-apical flux (B-to-A; mimicking brain to blood flux across the BBB)
flux, the substrate was added to the basolateral (lower) compartment, and samples were
collected from the apical compartment at different time points. At each time point, 100 µL
was sampled from the apical compartment. The same volume of transport buffer (without
substrate) was added back to the apical compartment to keep the total volume within the
compartment the same over the experiment. After the experiment, the amount of
substrate accumulated within the receiver compartment was measured by the appropriate
method (see specific sections below).
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BBB permeability
HIV-1 Tat and methamphetamine effects on BBB permeability were determined as
described above with some modifications. Lucifer yellow (100 μM, 0.521 kDa) was added
to the apical compartment and sampled from the basolateral (receiving) compartment at
different time points to assess the paracellular permeability. [3H]-propranolol flux across
the BBB was used to measure any changes in non-efflux transporter-mediated
transcellular transport. Propranolol (10 μM) crosses cells transcellularly, but its transport
is not influenced by active transport proteins, such as the efflux transporter P-gp (188).
Control values were determined by compound flux across the membrane inserts with no
cells. At the conclusion of the experiment, the amount of lucifer yellow within the
basolateral (receiver) compartment was measured using a 96-well fluorescence platereader (PHERAstar FS, BMG Labtech, Cary, NC) with appropriate excitation/emission
wavelengths. [3H]-propranolol concentrations were measured using a liquid scintillation
analyzer (Perkin-Elmer TriCarb 2800TR).
Antiretroviral Drug Flux across the BBB. HIV-1 Tat and methamphetamine effects on
antiretroviral flux across the BBB was determined as described above. The antiretroviral
drugs atazanavir and lopinavir were used in this study. A-to-B flux of both antiretroviral
compounds was measured. [3H]-atazanavir and lopinavir concentrations were measured
using liquid scintillation, and LC-MS/MS-based method developed by Wang et al.,
respectively (189).
Cellular Accumulation Experiments. hCMEC/D3 cells were grown to confluence in a
6-well tissue culture plate. Transport protein functional activity was analyzed by
measuring the intracellular accumulation of the substrates Rh123 (5 μM) and atazanavir
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(100 μM). hCMEC/D3 cells were treated with Tat (100 nM) and methamphetamine (10
μM) for 24 h. The cells were pre-incubated with HBSS buffer containing the P-gp inhibitor
verapamil (100 μM) and/or the MRP-1 inhibitor MK-571 (30 μM) for 30 min at 37°C
(temperature maintained throughout the experiment). Cells were washed with HBSS and
incubated with dosing solution containing Rh123 with and without inhibitor for one h. At
60 min, each well was washed twice with ice-cold HBSS and cells were lysed using NP40
buffer and 25× CPI. At the conclusion of the experiment, the intracellular content of Rh123
was measured using a fluorescence plate reader with appropriate excitation/emission
wavelengths. Atazanavir concentrations were measured using a liquid scintillation
analyzer. Intracellular drug accumulation was normalized to protein content for each well.
Western Blotting
Protein expression was analyzed by immunoblotting, using standard techniques.
hCMEC/D3 cells were treated for 24 h with Tat and methamphetamine, cells were lysed,
total protein was harvested, and protein concentrations were measured by Pierce BCA
protein assay. Twenty μg of cell lysate was loaded on 12% Mini-Protean TGX gel (BioRad, Hercules, CA) for all proteins, except ZO-1 where 7.5% Mini-Protein TGX gel was
used. Following electrophoresis and transfer to PVDF, the membrane was blocked in 5%
nonfat milk solution and incubated overnight in appropriate primary antibody. Antibodies
used include mouse anti-β-actin (1:4000, Sigma Aldrich, cat. A1978), mouse anti-Pglycoprotein (C219, 1:200 dilution, Covance, Princeton, NJ, cat. SIG-38710, rat antiMRP-1 (1:50 dilution, Kamiya Biomedical Company, Seattle, WA, cat. MC201) and rabbit
anti-ZO-1 (1:500) dilution, Life Technologies, Cat 402200). Blots were then incubated for
at RT for 1 h with the horseradish peroxidase-conjugated appropriate secondary
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antibodies [anti-mouse (1:20,000), anti-rabbit (1:20,000) or anti-rat (1:4000)]. Signals
were enhanced using chemiluminescence using SuperSignal West Dura System
(Pierce/Thermo Fisher Scientific) and detected by exposure to ChemiDoc system (BioRad). The chemiluminescence signal intensity was quantified using the ImageLab™
software (Bio-Rad). All protein expression data are expressed as relative density, which
was obtained by the ratio of the absolute density of transporter to that of β-actin.
Quantitative PCR methods
cDNA was prepared from 300 ng RNA per sample using the iScript kit (Bio-Rad)
according to the manufacturer’s instructions. Pre-designed TaqMan assays were
obtained from Life Technologies for ABCB1 (Hs00184500_m1) and ABCC1
(Hs01561483_m1). Quantitative PCR (qPCR) analysis was performed on a QuantStudio3
(Life Technologies) using three duplicates per sample, with five biological replicates per
condition, for both target and the endogenous control, human TBP (TATA-box binding
protein, Life Technologies). Each plate also included a serially-diluted standard sample
in addition to no template controls.
Data Analysis
Transport of compounds of interest are expressed in terms of apparent permeability
(Papp) and is described by the following equation
Papp = dX/Dt (A•Co), where dX/dT is mass of the transported compound (X) transported
over time (t), A is the surface area of the membrane insert, and Co is an initial
concentration in the donor compartment (190).
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Statistics
All the data was represented as mean ± SEM. TEER values, apparent permeability, and
western blots were compared by one-way ANOVA using Tukey’s post hoc test. Rh123
flux from apical to basolateral compartments (PappA-to-B) and the basolateral to apical
compartments (PappB-to-A) were compared by using two-way repeated measures ANOVA
with Tukey’s post hoc test. Intracellular accumulation of Rh123 and atazanavir with and
without transporter inhibitors were compared by two-way ANOVA using Tukey’s post hoc
test. The statistical analysis was performed in GraphPad Prism software, version 7.0. p
values < 0.05 were considered significant for all comparisons.
RESULTS

Cell Viability Studies
These studies were done using the LIVE/Dead™ assay to exclude the possibility that any
of the treatments might be cytotoxic to hCMEC/D3 cells under our experimental
conditions (Figure 3). Cells treated with a cytotoxic level (70%) of ethanol served as a
positive control for dead cells, while untreated cells served as positive control for live cells.
Our results showed that none of the treatments caused hCMEC/D3 cell death: Live cells:
Control cells 97 ± 0.7%, Tat 97 ± 1.6%, Meth 99 ± 0.4%, Tat + Meth 98 ± 0.5% and; Dead
cells: control 3 ± 0.7%, Tat 3 ± 1.6%, Meth 1 ± 0.4%, Tat + Meth 2 ± 0.5% (Figure 3A).
Tat and Methamphetamine Effects on Factors Affecting BBB Integrity
Transendothelial Electrical Resistance (TEER)
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Tight junctions form an impervious barrier between brain endothelial cells that hamper
free movement of ions. This charge difference is a measure of TEER. Higher TEER
values are indicative of a tighter barrier. TEER values were measured on consecutive
days, and the highest values were on days five and six, 44.9 ± 5.1 Ω * cm2 to 52.5 ± 4.7
Ω * cm2 (mean ± SEM), respectively (Figure 4A). Based on this observation, all the
experiments involving vectorial transport on transwell inserts were done on day 5, and
cells treated with Tat, methamphetamine, or Tat + methamphetamine on day four (24 h
before transport experiment). There was a significant decrease in TEER values in the Tat
only group (34 ± 2.4 Ω * cm2) as compared to control (42 ± 3.2 Ω * cm 2; p < 0.05),
suggesting impairment of barrier integrity upon Tat exposure. However, TEER values for
methamphetamine and Tat + methamphetamine treatments were not statistically
significant from controls (Figure 4B).
Tight Junction Expression
ZO-1 is tight-junction associated protein which anchors tight junction to the actin
cytoskeleton. It is responsible for maintaining integrity and tightness of the barrier (191).
Changes in expression of ZO-1 may lead to alteration of paracellular permeability across
blood-brain barrier (192). We measured the effect of Tat and methamphetamine on the
expression of ZO-1 protein in hCMEC/D3 cells via western blot (Figure 4C). Exposure to
HIV-1 Tat reduced ZO-1 expression by (58 ± 16%, p = 0.2137), methamphetamine
significantly reduced expression of ZO-1 (40 ± 18%, p = 0.0465), and HIV-1 Tat +
methamphetamine co-exposure also significantly reduced expression of ZO-1 (26 ± 15%,
p = 0.0132), as compared with controls (Figure 4C).
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Figure 3: Tat and methamphetamine effects on cell viability. A. The green portion of the bar represents the percentage of
live cells, and the red portion represents the percentage of dead cells. Data are represented as a mean percentage of live
or dead cells ± SEM from n = 3 independent experiments; each experiment was performed in duplicate. B. Fluorescent
images of cells labeled with calcein-AM (Live, Green) and ethidium homodimer (EthD-1) (Dead/dying, Red). Treatments (24
h) do not cause significant toxicity in endothelial cells as compared with vehicle-treated controls.
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Figure 4: Transcend thelial electrical resistance (TEER). A. TEER values were measured each day in culture to establish
optimal days for conducting the experiments (n = 3-8 experiments). Maximal TEER (value) was achieved on day 6. B. Tat
alone significantly reduced TEER values across the hCMEC/D3 cell barrier (*p < 0.05 vs. control); mean ± SEM from n = 810 independent experiments per group; each experiment consisted of duplicate or triplicate samples. C. Western blot of
ZO-1 tight junction-associated protein and β-actin used as loading control. Each bar represents density ratio of ZO-1 to βactin expressed as percent control, mean ± SEM. Methamphetamine alone or combined Tat and methamphetamine
significantly reduced expression of ZO-1 in hCMEC/D3 cells as compared to vehicle-treated controls (*p <0.05).
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P-glycoprotein is expressed and functional in hCMEC/D3 cells
P-gp expression in the hCMEC/D3 cells of the BBB was confirmed by western blot (Figure
5A), and P-gp function was assessed using two approaches. First, intracellular
accumulation of the P-gp substrate, Rh123 was determined in cells grown on standard,
24-well culture dishes (not a transwell format). To determine the role of P-gp in Rh123
accumulation, the experiments were performed under control conditions (no inhibitor) or
in the presence of verapamil, a P-gp inhibitor. Inhibition of P-gp-mediated efflux of Rh123
by verapamil resulted in a 78% increase in the cellular accumulation of Rh123 (p < 0.05)
(Figure 5B). Second, the bidirectional transport of Rh123 was studied in the BBB model
in which hCMEC/D3 cells were grown on transwell membrane inserts. Apical to
basolateral (A-to-B; representing blood to the brain) transport and basolateral to apical
(B-to-A; representing brain to blood) transport of Rh123 was measured at 15, 30, 45 and
60 min. Apparent permeability (Papp) was calculated for transport in both directions
(Figure 5C). The Papp of Rh123 in the B-to-A direction (5.27×10-3 cm/min) was two-fold
greater than apparent permeability in the A-to-B direction (2.88×10-3 cm/min), consistent
with the active efflux of Rh123 in the B-to-A direction (Figure 5C).

Tat and Methamphetamine Effects on Flux across the BBB
Paracellular Flux
Lucifer yellow (LY, 100 µM) traverses the BBB via the paracellular route (193). Control
Papp values from our lab are consistent with those reported by others (194). hCMEC/D3
cells were treated with Tat, methamphetamine or Tat + methamphetamine 24 h before
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experiment (195). Lucifer yellow Papp in the A to B direction was determined. No
significant changes were observed in Papp values following 24 h exposure to Tat,
methamphetamine, or Tat + methamphetamine (Table 4).
Transcellular Flux
Propranolol, a basic lipophilic drug that traverses the barrier via transcellular transport
was added on to the upper chamber. Propranolol is not a known substrate for efflux
transporters (196). The transcellular barrier in our model (as measured by, Papp of
propranolol, 2.28 × 10-3 cm/min) was lower than in previously reported studies (4.5 × 10 3

cm/min), suggesting the barrier was less permeable to propranolol than what was

reported by others (197). Papp was calculated for all the treatments. No significant
changes were observed in Papp values for propranolol following 24 h exposure to Tat,
methamphetamine, or Tat + methamphetamine, as was expected (Table 4).
Lopinavir and atazanavir are protease inhibitors used in the treatment of HIV-1 infections.
Penetration of these drugs to the brain is limited by extrusion of these drug through efflux
transporters expressed on the luminal side of BBB. We studied antiretroviral drug
transport in our in vitro model of BBB.

The cells were exposed to Tat and/or

methamphetamine for 24 h and apparent permeability of these drugs was calculated to
study relative penetration of these drug across BBB in the presence of treatments. None
of the treatments caused significant changes in net permeability of atazanavir or lopinavir
in the transwell format (Table 4).
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Figure 5: P-glycoprotein expression and function. A. Western blot demonstrating the expression of P-glycoprotein in
hCMEC/D3 cells, with β-actin used as loading control. Caco-2 and P-gp-overexpressing MDCK cells were used as positive
controls. Jurkat cells were used as the negative control for P-gp expression. B. P-gp-mediated intracellular accumulation of
rhodamine 123 (Rh123) ± the P-gp inhibitor verapamil. Verapamil significantly increases the intracellular accumulation of
Rh123. C. The flux of Rh123 is asymmetric in the BBB model, demonstrating greater transport of Rh123 in the B-to-A
direction as compared to the A-to-B direction, consistent with active efflux mechanisms. Data are presented as the mean ±
SEM from n = 3 independent experiments; each experiment was performed in triplicate; (*p < 0.05).
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Table 4: Apparent Permeability from (apical to basolateral side) (Papp) cm/min
Drug

Control (SEM)

Tat (SEM)

Meth (SEM)

Tat + Meth (SEM)

Atazanavir

5.64×10-4
(1.16×10-4)

6.08×10-4
(1.45×10-4)

6.41×10-4
(1.86×10-4)

4.86×10-4
(1.42×10-4)

Lopinavir

6.20×10-3
(2.41×10-3)

5.57×10-3
(2.24×10-3)

8.33×10-3
(3.79×10-3)

9.72×10-3
(4.88×10-3)

Propranolol

2.28×10-3
(3.26×10-4)

2.04×10-3
(2.36×10-4)

1.92×10-3
(1.48×10-4)

1.93×10-3
(1.36×10-4)

Lucifer
Yellow

1.11×10-3
(6.94×10-5)

1.15×10-3
(7.82×10-5)

1.18×10-3
(1.16×10-4)

1.19×10-3
(8.56×10-5)

Table 4: Apparent permeability (Papp) of substrates/drugs measured from their passage from upper to lower chamber (Ato-B) of transwell system in hCMEC/D3 cells treated with Tat, methamphetamine, or Tat plus methamphetamine for 24 h.
Propranolol is a lipophilic drug and a marker for transcellular transport, while Lucifer yellow is a marker for paracellular
transport. Atazanavir and lopinavir are the protease inhibitors used in the treatment of HIV infection. Papp is represented
as the mean ± the standard error of mean (SEM), *p <0.05, for n = three independent experiments done in triplicate. There
was no statistically significant difference in Papp for any antiretroviral drugs in hCMEC/D3 cells treated with Tat,
methamphetamine, or combined Tat and methamphetamine when compared to controls.
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Intracellular Drug Accumulation
Rhodamine123
Rh123 passively diffuses into the hCMEC/D3 cells and is then subject to being expelled
from the cell by the efflux transporter P-gp. When hCMEC/D3 cells were treated with the
P-gp inhibitor verapamil, Rh123 accumulation within the cell increased significantly (p <
0.0002) (Figure 5B). Next, Rh123 accumulation in the cells treated with Tat and/or
methamphetamine was studied to assess the effects of treatment of P-gp mediated efflux
activity. When compared to control, only the Tat + methamphetamine experimental group
showed a significant increase in intracellular accumulation of Rh123 (*p = 0.0182) (Fig.
5). This suggests that Tat + methamphetamine co-exposure may influence P-gp
expression or function within our BBB model. To further evaluate the influence of Tat and
methamphetamine on P-gp, similar experiments were performed with Rh123 but also in
the presence of the P-gp inhibitor, verapamil (Figure 6). As would be expected in cells
with functional P-gp, inhibition of P-gp by verapamil decreased efflux of Rh123 and
resulted in significant increases in Rh123 intracellular accumulation in the control group
(*p = 0.0004). The increase in Rh123 within the cell upon P-gp inhibition was also
observed with the Tat only (*p = 0.0085) group (Figure 6), again consistent with the finding
that exposure to Tat alone does not alter P-gp function. Verapamil inhibition did not alter
the intracellular accumulation of Rh123 in the methamphetamine, and Tat +
methamphetamine group, suggesting that P-gp function was already impaired after
exposure to these treatments.
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Atazanavir
The apparent permeability studies described above, did not demonstrate a significant
difference in net atazanavir flux across the membrane in either the A-to-B direction
(control 2.23 × 10-3 cm/min, Tat 2.22 × 10-3 cm/min, methamphetamine, 2.23 × 10-3
cm/min, Tat + methamphetamine 2.28 × 10-3 cm/min) (Table 4) or B-to-A (data not
shown). However, many antiretroviral drugs, including atazanavir, are substrates of
transporters such as P-gp and MRPs. In order to assess the role of efflux transporters in
drug accumulation inside hCMEC/D3 cells, and effects of Tat and/or Meth on the function
of P-gp and MRPs, intracellular accumulation of atazanavir was studied in hCMEC/D3
cells in a non-transwell format in vitro.
Intracellular accumulation of atazanavir was not significantly different across Tat and/or
methamphetamine treatment groups (Figure 7). Thus, accumulation of atazanavir was
examined in the presence of P-gp and MRP inhibitors (verapamil and MK-571,
respectively), individually as well as both inhibitors together. Surprisingly, neither P-gp
inhibition alone nor MRP inhibition alone resulted in significant changes in atazanavir
intracellular accumulation (Figure 7). To test whether P-gp or MRP transporters might
compensate for one another if either alone is inhibited, we simultaneously inhibited both
transporter classes. Interestingly, when P-gp and MRPs (verapamil + MK-571) were both
inhibited, there was a significantly higher accumulation of atazanavir compared to groups
lacking the inhibitors (p < 0.05) suggesting atazanavir is shunted to the alternative efflux
transporter if either P-gp or MRPs are blocked. Therefore, the maximum accumulation of
atazanavir was observed when both P-gp and MRPs are inhibited concurrently (Figure
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7). Irrespective of whether P-gp and/or MRPs are inhibited, however, neither Tat nor
methamphetamine had effects on the overall accumulation of atazanavir.
Effects of Tat and/or Methamphetamine on protein/ gene expression of P-gp and
MRP
We assessed the effects of Tat and/or methamphetamine on P-gp and MRP1 gene and
protein expression by qPCR and immunoblotting. All qPCR experiments performed within
expected parameters and standard curves showed good linear relationships between
serial dilutions (min R2 > 0.989). Using the untreated samples as a reference, P-gp
expression in hCMEC/D3 cells showed no significant changes following treatment with
Tat, methamphetamine, and Tat + methamphetamine. Similarly, MRP1 showed no
significant change following treatment with Tat, methamphetamine, and Tat +
methamphetamine (data not shown).
Similarly, no statistically significant differences in the expression of P-gp or MRP1
proteins between the experimental groups was observed (Figure 8). Therefore, no
changes in mRNA or protein expression of P-gp or MRP1 were observed after 24 h
exposure of hCMEC/D3 cells to Tat, methamphetamine, or Tat + methamphetamine.
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Figure 6: Tat and methamphetamine effects on Rhodamine123 intracellular accumulation. Effects of 24 h exposure to Tat
and/or methamphetamine on P-gp mediated Rh123 accumulation. Open circles and solid circles represent the accumulation
of Rh123 in the absence and presence of verapamil, respectively. In the absence of verapamil (open circles) there was
significantly higher accumulation in Tat + methamphetamine group when compared to control or compared to Tat only
group, consistent with an impairment of P-gp (and thus less efflux of Rh123 out of the cell) upon exposure to Tat +
methamphetamine. Inhibition of P-gp by verapamil (solid circles) significantly increased Rh123 accumulation in control and
Tat only group, which would be expected for cells with functional P-gp. All symbols represent intracellular accumulation of
Rh123 (nanomol/mg protein); mean ± SEM from n = 5 independent experiments; each experiment was performed in
triplicate (*p < 0.05, verapamil vs. the identical treatment without verapamil, #p < 0.05, groups treated without verapamil).
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Figure 7: Atazanavir intracellular accumulation studies. Effect of 24 h exposure of Tat and/or methamphetamine on
atazanavir accumulation in hCMEC/D3 cells under control conditions (open circle), inhibition of P-gp by verapamil (solid
circle), inhibition of MRPs by MK-571 (open square), and inhibition of both P-gp and MRPs by verapamil + MK-571 (inverted
triangle). Treatment with Tat and/or methamphetamine did not affect atazanavir intracellular accumulation under any
conditions (± inhibitors). However, regardless of the treatment group, when P-gp and MRP-1 were inhibited together,
atazanavir intracellular accumulation was significantly increased as compared to the same groups with no inhibitor (*), MK571 (#), and verapamil (⊗). These data suggest that inhibition of a single transporter is not sufficient to alter the intracellular
accumulation of atazanavir, perhaps because the substrate shunts from the inhibited transporter to the functional
transporter. Symbols represent atazanavir accumulation in mean ± SEM for different inhibitor conditions (open circle-no
inhibitor, open square-MK-571, solid circle-verapamil, inverted triangle-MK-571+verapamil; mean ± SEM from n= 3
independent experiments per group; each experiment performed in triplicate (*p < 0.05, no inhibitor vs verapamil + MK–
571, #p < 0.05, MK-571 vs verapamil + MK-571, ⊗p < 0.05, verapamil vs verapamil + MK-571
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Figure 8: Immunoblots of P-gp and MRP-1. Western blots of P-gp (A) and MRP-1 (B) from the cell lysate of hCMEC/D3
cells exposed with Tat and/or methamphetamine for 24 h. Treatments had no significant effect on the expression of Pglycoprotein (P-gp) or Multidrug Resistant Protein-1 (MRP-1). Each bar represents the mean ± SEM of the relative density
of the drug efflux protein (absolute density of P-gp or MRP-1 to the absolute density of β-actin) for n = 4 independent
experiments (*p < 0.05).
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DISCUSSION
The purpose of these studies was to investigate the effects of HIV-1 Tat and
methamphetamine on factors affecting antiretroviral penetration, such as paracellular and
transcellular pathways of drug flux across the BBB. We hypothesized that Tat and
methamphetamine exposure would result in BBB breakdown and that the loss of integrity
would disrupt antiretroviral drug flux. To address these questions, an in vitro BBB model
was used to explore the effects of treatment on different aspects of paracellular and
transcellular transport. Since both Tat, and to lesser extent methamphetamine, can be
intrinsically cytotoxic, we assessed the effects of treatments acutely before breakdown of
the cellular barrier. Methamphetamine effects on the BBB are complex, and further
investigations of temporally related changes may be necessary. Additionally, treatment
effects on antiretroviral penetration are mediated by multiple transport systems, and this
redundancy may help abrogate Tat- or methamphetamine-induced alterations in a single
transport protein. Overall, our results demonstrate that in combination Tat and
methamphetamine affect aspects of barrier integrity without affecting the net flux of
paracellular compounds, and also may alter key aspects of transcellular transport.
Effects of Tat and methamphetamine on paracellular integrity
Following 24 h exposure to Tat, TEER values (a measure of BBB tightness or integrity)
were significantly decreased. The data complement findings by Mahajan et al., which
found reductions in TEER in Tat-treated primary human brain microvascular endothelial
cells co-cultured with astrocytes (106). Methamphetamine exposure (regardless of Tat)
resulted in significant decreases in ZO-1 protein expression in this model. Interestingly,
no effects of Tat or methamphetamine on lucifer yellow (a paracellular marker) flux were

69

noted, despite reports that methamphetamine disrupts the BBB. The published reports of
methamphetamine effects on the BBB are often inconsistent. This is likely due to the
highly varied model systems and experimental protocols used in these studies.
Furthermore, many of the studies used methamphetamine concentrations that are more
than the plasma concentrations found in typical drug abuse (198). The use of extremely
high concentrations may result in direct neurotoxic stress which, in turn, could lead to
BBB breakdown (199, 200). Our studies used 10 µM concentrations, which is within the
range of plasma concentrations measured from methamphetamine abusers (0.1-11.1
µM) (187) and we demonstrated lack of toxicity at this concentration using the LIVE/DEAD
assay.

Other factors that contribute to the complexity of interpretation of

methamphetamine effects on the BBB is that methamphetamine exposure times vary
widely between studies. In one study of high dose (30 mg/kg) methamphetamine
exposure in mice, barrier permeability to the paracellular compound Evans blue was
altered, albeit transiently; increase observed at 24 h, but not 72 h (109). In another study
using primary rat brain microvascular endothelial cells, investigators observed that TEER
values initially decreased but recovered over the four h following methamphetamine
exposure (for both 1 μM and 50 μM methamphetamine) (108). In the same study, the
lateral continuity of the tight junction proteins VE-cadherin, occludin, claudin-5, and ZO-1
was maintained following methamphetamine (1 μM) exposure, albeit only 2- and 6-h time
points were reported (we observed decreases following 24 h exposure). However,
increases in vesicular transport, unrelated to paracellular transport, were noted for cells
treated with 1 μM, but not 50 μM, methamphetamine (108). In brain capillaries from
methamphetamine-treated mice, transient increases in claudin-5 and occludin, but not
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ZO-1 protein, were demonstrated by western blot at 3 h and returned to baseline levels
by 24 h (110). Lastly, decreases in the expression of tight junction proteins at 12 h and
24 h (10 μM) without changes in paracellular permeability (111), and decreases in TEER
without changes in tight junctions for up to 72 h also have been reported (106).
Collectively, these studies provide evidence for potentially transient and complex
interactions of methamphetamine on the BBB, and that the effects of methamphetamine
on the BBB are related to dose, exposure duration, and specific experimental model used.
Given the variability among published studies, future studies should further explore the
temporal nature of this complex interaction and should consider examining in intact
systems in vivo to increase the physiological and translational relevance.
Effects of Tat and methamphetamine on transcellular flux
Propranolol crosses the barrier transcellularly, but is not a substrate for drug efflux
proteins (58). Tight junction modulation often alters paracellular flux but does not always
confer changes in transcellular transport (201, 202). Therefore, neither tight junction
protein modulation nor changes in drug efflux proteins were expected to alter the flux of
propranolol in these experiments. Indeed, we observed no changes in propranolol flux
across the barrier in response to exposure to Tat- and/or methamphetamine.
P-gp is a major drug efflux protein responsible for extrusion of substrates from the brain
back into the blood. Several antiretroviral drugs used in the treatment of HIV are
substrates for P-gp, limiting brain exposure to these medications, and other antiretrovirals
are inducers or inhibitors of P-gp (203–210). Tat- and/or methamphetamine-induced
modulation of P-gp expression or function may affect the ability of these antiretrovirals to
cross the BBB. The inability of antiretroviral drugs to enter the CNS, in turn, would limit
the ability of the therapeutic regimen to reduce viral loads within the brain.
71

Using Rh123 as a prototypical P-gp substrate (211), the effects of Tat and
methamphetamine on Rh123 flux were measured in our model system. Tat exposure did
not affect the overall accumulation of Rh123 into cells lacking the inhibitor. In the presence
of the known P-gp inhibitor verapamil, Rh123 accumulated in Tat-treated cells (73%
increase) and by 93% in controls. Taken together, these data suggest that P-gp was
functioning normally and that the transporter was unaffected by exposure to Tat alone.
Tat exposure (up to 12 h) was previously shown to increase P-gp expression and function
in primary mouse brain microvascular cells (177). Differences between our results and
those reported by Hayashi et al. might result from differences in the Tat protein used
(Hayashi used Tat1-72 versus Tat1-86 in our study), Tat concentration, or the duration of
exposure, as well as differences in the origins of the cells used in the BBB model.
Exposure to Tat + methamphetamine resulted in the increased cellular accumulation of
the P-gp substrate, Rh123, in brain microvascular endothelial cells. This suggests that Pgp was inhibited or impaired P-gp function within these cells. When the Tat +
methamphetamine-exposed

group

was

treated

with

verapamil,

no

additional

accumulation of Rh123 was observed (Fig. 5), suggesting that P-gp function was
maximally impaired after exposure to methamphetamine. The changes in P-gp function
in these experiments were not accompanied by significant alterations in gene or protein
expression at 24 h (Fig. 5). Others have reported methamphetamine exposure increasing
P-gp protein expression (at 3 h), but its effects at other time points and the functional
consequences thereof have not been reported (110). Other amphetamines, including
MDMA, have been shown to have inhibitory effects on P-gp activity but effects of
methamphetamine itself on P-gp function were not reported (212). Given the transient
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nature of methamphetamine effects on other properties of the BBB discussed above,
further investigation into the effects of methamphetamine exposure on drug efflux
transporters, such as P-gp, is warranted.
Atazanavir is a protease inhibitor used in the treatment of HIV and is a known substrate
for P-gp and several MRPs (213). To evaluate potential effects of Tat and
methamphetamine on brain penetration of antiretroviral drugs, we examined the effects
of Tat and methamphetamine on atazanavir flux across the BBB using the transwell
system as well as atazanavir accumulation within cells. Tat and methamphetamine did
not result in changes in atazanavir flux under either experimental system, nor were their
significant alterations in gene or protein expression of MRP1 or P-gp. Prior experiments
using Rh123 indicated that P-gp function (but not expression) was impaired in the
presence of methamphetamine. Therefore, to verify the role of P-gp and the MRPs on the
flux of atazanavir in our system, additional cellular accumulation studies were performed
in the presence of verapamil and/or MK-571 (an MRP inhibitor). When single inhibitors
were used (either verapamil or MK-571), no significant changes in intracellular atazanavir
accumulation were observed. However, for all treatment groups, simultaneous inhibition
of P-gp and MRP resulted in significant increases in atazanavir intracellular accumulation
as compared to the same groups with no either no inhibitor or single transport inhibition
(Fig. 6). These data suggest that inhibition of a single transporter is not sufficient to alter
the intracellular accumulation of atazanavir, perhaps because the redundancy of two
efflux transport proteins allows for substrate shunting from the inhibited transporter to the
functional transporter.
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Taken together, these data support previous reports that atazanavir is a substrate for both
P-gp and MRP, but that neither Tat nor methamphetamine significantly alter the net flux
of atazanavir efflux in our system. Another potential explanation for the seeming
discrepancy between effects of Tat and methamphetamine on P-gp-mediated transport
of Rh123 and atazanavir can potentially be explained by differences in uptake
mechanisms for each substrate. At the concentrations used in these studies, Rh123
enters the cell primarily by passive diffusion (214), whereas atazanavir cellular uptake
has been shown to be mediated by organic anion transporting polypeptide (OATP) uptake
transporters as well (215). Therefore, Tat and/or methamphetamine exposure in our
system would not be expected to alter Rh123 entry into the cell; but may, indeed, alter
OATP-mediated uptake of atazanavir. Future studies should explore the effects of Tat
and methamphetamine on OATP and on OATP-mediated antiretroviral transport.
Understanding the role of efflux transporters may have implications beyond restricting
access to the CNS. P-gp can also be expressed by microglia and astrocytes—the
principal resident cell types that are infected within the CNS—suggesting that even if a
drug such as atazanavir enters the CNS, it may be difficult to achieve therapeutic
concentrations within HIV-infected cells in the CNS (179, 216). Moreover, P-gp
expression in rat astroglia can be downregulated by HIV gp120 resulting in a net decline
in P-gp function (179, 180). By contrast, others report that HIV Tat can upregulate P-gp
in brain endothelial cells (177, 178), which may occur before onset of the more cytotoxic
effects of Tat through the release of inflammatory intermediaries such as cytokines or
oxyradicals, or prior to activation of cell death pathways (153). The evidence infers that
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the effects of HIV on efflux transporters are complex and may differ depending on the
particular HIV protein and transporter involved, and the duration of exposure.
Collectively, our investigations indicate that HIV-1 Tat and methamphetamine alter
aspects of BBB integrity and antiretroviral flux across the barrier. Dysregulation of drug
transport proteins occurs, and the resultant net effects on the transport of an antiretroviral
drug into the brain are dependent on the specific transport system involved. The
interactive effects of Tat and methamphetamine on drug transport are complex and likely
related to the particular antiretroviral agent involved, and its dose and exposure duration.
Future directions should include a thorough investigation on the temporal effects of HIV
and methamphetamine on other drug transporters such as the MRPs, as well as the
uptake transporters that have a role in antiretroviral entry into the cell.
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Simultaneous determination of intracellular concentrations of tenofovir,
emtricitabine, and dolutegravir in the human brain microvascular endothelial cells
using liquid chromatography-tandem mass spectrometry
INTRODUCTION
According to the Joint United Nations Program on HIV/AIDS (UNAIDS) report of 2018,
36.9 million people globally are living with Human Immunodeficiency Virus (HIV) (9). In
the early years of the HIV epidemic, post-diagnosis survival rates were measured in
months. With the advent of combination antiretroviral therapy (cART), patients are better
able to achieve and maintain plasma viral suppression, and survival rates of individuals
living with HIV have reached a near normal lifespan (35). However, even for patients who
can achieve viral suppression within the blood, HIV persists within the central nervous
system (CNS). The persistence of HIV and the resultant chronic inflammation likely
contribute to the development of neurocognitive deficits experienced by many persons
infected with HIV (60, 61, 217). Approximately, 50-60% of individuals infected with HIV
suffer from HAND, which is a spectrum of neurocognitive impairment ranging from
asymptomatic neurocognitive impairment to full-blown dementia (218–220).
Poor brain penetration of antiretroviral drugs likely contributes to the persistence of HIV
within the brain (221). Antiretroviral penetration into the brain is mediated, in part, by the
blood-brain barrier (BBB), which restricts the entry of the drugs into the central nervous
system (CNS), and by uptake and efflux transport proteins that are expressed at the
luminal side of BBB (126). Depending on the physicochemical properties of the drug or
substrate, efflux transport proteins can either facilitate or impede xenobiotic entry into the
brain (222). Furthermore, the net flux of drugs into the cytoplasm of individual cell types
within the CNS is also mediated by transport proteins, which are integral membrane
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proteins expressed at the cell surface. Drug efflux proteins, such as P-glycoprotein and
Breast Cancer Resistance Protein (BCRP) are transport systems that can actively extrude
substrates, including several antiretroviral drugs, out of the cell on which they are
expressed (13, 223); thereby limiting the overall intracellular concentrations of
antiretroviral drugs (224). In contrast, uptake transporters, when located on the luminal
side of the BBB facilitate the movement of substrates across the BBB and into individual
cells (225).

Human brain microvascular endothelial cells, the primary cellular constituent of the BBB,
form the lining of brain microvessels. Through the expression of tight junction proteins,
these cells form a tight intercellular barrier that restricts the entry of toxins, and other
foreign substances, including xenobiotics, across the BBB, and into the brain (226).
Structural and functional deficits in brain microvascular endothelial cells are critical in
advancing the neuropathogenesis of HIV (227). These cells are the site of entry of free
circulating virus, as well as the entry point for HIV infected monocytes, to pass through
the barrier and enter the brain (64, 228). Moreover, human brain microvascular
endothelial cells may also be a site of HIV replication (229–231). In this study, we
developed and validated an assay for simultaneous quantification of three antiretroviral
drugs and applied this method in the quantification of antiretroviral concentrations within
an immortalized human brain microvascular endothelial cell line (hCMEC/D3). The
hCMEC/D3 cell line has been widely used as a model of primary human brain
microvascular endothelial cells and in the construction of an in vitro BBB model (132, 194,
232, 233). The hCMEC/D3 cells mimic key aspects of primary endothelial cells and

77

display characteristics of the BBB, including the expression of tight junction proteins, the
uptake and efflux transport proteins, the expression of chemokine receptors (including
HIV-1 co-receptors), and they also can regulate the expression of cellular adhesion
molecules in response to inflammatory cytokines (132).
Because HIV enters and replicates within infected cells, intracellular drug concentration
is important factor in determining the efficacy of an antiretroviral drug. Several
antiretroviral drug classes including the nucleoside reverse transcriptase inhibitors
(NRTIs), nucleotide reverse transcriptase inhibitors (NtRTIs), non-NRTIs (NNRTIs),
integrase inhibitors, and protease inhibitors (PIs) act on intracellular targets. As discussed
above, the intracellular accumulation of antiretroviral drugs is dependent on several
factors, including drug transport protein expression and activity, which varies among
different cell types (131, 234–236). There is also evidence of tissue-specific differences
in the penetration of antiretroviral drugs within cerebral cortical, female genital tract tissue,
and lymphoid compartments when compared to blood, which may affect the efficacy of
antiretroviral therapy (237, 238). Accordingly, the goal of this study was to develop an
assay to simultaneously measure the intracellular concentration of multiple antiretroviral
drugs within a clinically relevant drug regimen.
For this study, the cART regimen of a nucleoside reverse transcriptase inhibitor (NRTI),
emtricitabine, a nucleotide reverse transcriptase inhibitor (NtRTI), tenofovir, and an
integrase strand inhibitor, dolutegravir, was used (Figure 9). This regimen is currently one
of the recommended initial regimens for most people with HIV (239). These drugs have
previously been quantified, individually or simultaneously, in either human plasma or
peripheral blood mononuclear cells or mouse plasma (240–244). To best of our
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knowledge, this is the first study quantifying the intracellular concentrations of these three
antiretroviral drugs simultaneously in human brain microvascular endothelial cells.

Figure 9: Chemical structure of tenofovir, emtricitabine, and dolutegravir
METHODS

Chemical and reagents
Tenofovir and emtricitabine were obtained from the United States Pharmacopeia
(Rockville, MD). Dolutegravir was purchased from TLC PharmaChem (Ontario, Canada).
For cellular accumulation studies, the following drugs were obtained through the NIH
AIDS Reagent Program, Division of AIDS, NIAID, NIH: Tenofovir, Emtricitabine [(-) FTC].
Dolutegravir was purchased from Sigma Aldrich. Tenofovir-d6 and emtricitabine-13C
15N2 were obtained from Toronto Research Chemical Inc. (Ontario, Canada).
Dolutegravir-d5 was purchased from BDG Synthesis (Wellington, NZ).

Methanol,

acetonitrile with 0.1% formic acid, and 2-propanol (HPLC grade) were obtained from
Honeywell Chemicals (Muskegon, MI). Ultrapure water was collected from Milli-Q®
(Molsheim, France) integral water purification system. 6-well plates used in these studies
were from Corning Inc. (Corning, NY, USA). Human brain microvascular endothelial cells,
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hCMEC/D3, were generously provided by Dr. Babette Weksler of Weill Cornell Medical
College, Cornell University (New York, NY). Endothelial basal media (EBM-2) and the
EGM2-MV Bullet kit were purchased from Lonza (Basel, Switzerland). GIBCO® HBSS
(Hank’s Balanced Salt Solution), penicillin-streptomycin (10,000 U/mL), HEPES [(4-(2hydroxyethyl)-1-piperazineethanesulfonic acid)] was obtained from Thermo Fisher
Scientific (Waltham, MA). The EGM2-MV Bullet kit contained human endothelial growth
factor (hEGF), insulin-like growth factor (IGF), human fibroblast growth factor (hFGF),
vascular endothelial growth factor (VEGF), hydrocortisone, ascorbic acid, FBS, GA-1000
(gentamycin and amphotericin). 0.45 µm MultiscreenHTS filter plate was purchased from
Millipore (Millipore sigma, USA)
Cell culture
hCMEC/D3 were grown in EBM-2 media supplemented with EGM2-MV bullet kit at 5%
CO2, 37°C and 95% relative humidity. This medium was called growth medium for
hCMEC/D3 cells. Cells seeded on 6-well plates were grown on EBM-2 media
supplemented with 1.25% FBS, 5 mL of penicillin/streptomycin solution (10,000 U/mL), 5
mL of 10 mM HEPES and 1.25 mL of 0.5 ng/mL bFGF. This media was referred to as
maintenance media.
Chromatography
The HPLC system consisted of an Agilent 1260 Series HPLC system (Agilent
Technologies, Palo Alto, CA, USA), a Shimadzu, System Controller, SCL-10A Vp, Pump,
LC 10AD Vp Solvent Degasser (DGU14A, Shimadzu, Columbia, MD, USA), and an CTC
PAL autosampler (Zwingen, Switzerland). The analytical column was XBridge C 18, 50 x
2.1 mm, 5µm (Waters Corp, Milford, MA, USA). The column temperature was maintained
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at 25 °C. Mobile phase A was water and mobile phase B was 0.1 % formic acid in
acetonitrile. The elution pump (Agilent 1260) gradient was: 0–1.0 min 0.0% B at 0.4
mL/min flow, 1.1–3.0 min from 50% to 90% B at 0.4 mL/min flow rate, 3.1–7.0 min 90%
B at 0.8 mL/min flow rate and 7.1–10.0 min 0.0% B at 0.8 mL/min flow rate. The makeup
pump (Shimadzu) ran an isocratic gradient at 50:50 mobile phase A: mobile phase B and
at a flow rate of 0.2 mL/min. The switching valve program was: 0-1.8 min at position A
(loading sample into column and desalting), 1.8-3.0 min at position B (elution to MS
source) and 3.0 to 10.0 min at position A (column flushing and re-equilibration). Injection
volume was 50 µL and total run time was 10.0 min.
Mass spectrometric conditions
The Mass Spectrometer was an AB Sciex API 4000 system (Applied Biosystems Sciex,
Ontario, Canada) using Analyst 1.6.3 software, which was operated in the electrospray
ionization (ESI) positive multiple reaction monitoring (MRM) modes. The MS/MS
parameters were; ions source temperature (500.0 °C), ion spray voltage (5000 V),
electron multiplier CEM (2400 V), Collison gas flow CAD (8.0), curtain gas flow CUR
(25.0), nebulizer gas floe NEB/GS1 (45.0), turbo ion spray gas AUX/GS2 (45.0), deflector
potential DF (-150), pause time 95 ms). Mass transitions and optimized MRM parameters
are shown in (Table 5).
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Table 5: Mass spectrometric parameters
Drugs

Q1

Q3

DP

CE

EP

CXP

Tenofovir

288.2

175.9

64

36.00

10

12.07

Tenofovir-d6

294.3

182.2

64

37.11

10

10.07

Emtricitabine

248.1

130.0

36.74

19.09

10

8.98

Emtricitabine-13C 15N2

251.3

133.0

36.75

15.07

10

8.98

Dolutegravir

420.1

277.0

81.97

37.95

10

20.59

Dolutegravir-d5

425.3

277.2

83

36.70

10

19.78

Q1 =Quadrapole mass filter 1 (Q1) and 3 (Q3), DP= Declustering potential (Volts)
CE= Collision Energy (Volts), EP= Entrance Potential (Volts), CXP= Collision Cell Exit
Potential

Cell Extract Preparation
hCMEC/D3 cells were grown in T75 flasks as described above. At 90% confluency, cells
were washed twice with 9.5 mL of ice-cold Hank’s Balanced Salt Solution (HBSS), and
cells were lysed with a 15 min ice-cold methanol (9.5 mL) incubation followed by scraping
of the cells. The resulting cell extracts were stored at -80°C.
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Stock Preparation
Stock solutions of tenofovir, tenofovir-d6, emtricitabine, emtricitabine-13C6,

15N
2

were

prepared in ultrapure water at a concentration of 100 µg/mL. Dolutegravir, dolutegravird5 stock solutions were prepared in DMSO at a concentration of 100 µg/mL. Subsequent
dilutions were made in water for spiking calibration standards and quality control samples.
All stock solutions were stored at 4-8°C in amber colored glass bottles.
Preparation of Calibration Standards and Quality Control (QC) samples
Samples were vortex mixed for 1.0 min at 750 rpm then centrifuged for 5 min at 4696 x
g. Two hundred microliters of each sample were aliquoted into a 96-well plate (VWR®
Microplate, pyramid bottom, 2 mL well volume) and 20 µL of 50 ng/mL working internal
standard solution was added. Sample plate were vortex mixed for 5 min at 750 rpm and
centrifuged for 15 min at 6102 x g, and 150 µL of supernatant was collected, filtered
through a 0.45 µm multiscreen HTS filter plate (centrifuged for 5 min at 3500 x g) and
dried under a steady stream of nitrogen gas at 45°C. The dried extracts were
reconstituted with 150 µL of ultrapure water, mixed for 10 min at 1200 rpm. Moreover,
centrifuged again for 15 minutes at 6102 x g. Lastly, 50 µL of the final extract was injected
into LC-MS/MS.
Method Validation
The developed LC-MS/MS method was validated for linearity, precision, and accuracy
according to the FDA bioanalytical guidance for these parameters (245).
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Linearity and lower limit of quantification (LLOQ)
Cell lysate calibration curves were constructed by plotting peak area ratio of each analyte
to its corresponding labeled internal standard versus standard concentrations. Ten
calibration standards in duplicates over five validation runs were constructed using a
linear 1/concentration squared weighted least-squares regression algorithm. The lower
limit or quantitation (LLOQ) was defined as the lowest concentration on the calibration
curve with precision (calculated as percent relative standard deviation; % RSD) and
accuracy (calculated as percent difference from nominal; % DFN) within ± 20%. For the
rest of the levels on calibration curve precision and accuracy (as defined above) should
be within ± 15%.
Selectivity
Six blank cell extracts from hCMEC/D3 cells at six different passages were processed in
the same fashion as samples (see sample preparation). The selectivity of this assay was
assessed by comparing LLOQ level and blank cell extracts. To assess for possible
interference from blank cell matrix, no peaks in blank cell extracts should be greater than
20% response of LLOQ.
Accuracy and Precision
Accuracy and precision were evaluated using six QC levels (LLOQ, Low-QC, MedLow
QC, Med-QC, MedHigh-QC, and High-QC). Intra-day accuracy and precision were
determined by analyzing six replicates at each QC level in a single assay. Inter-day
accuracy and precision were determined by analyzing three replicates of each QC level
except LLOQ in five independent runs. To validate the dilution integrity of above the
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ULOQ samples; dilution QC samples (200 ng/mL) were diluted threefold and analyzed in
six replicates in one validation run. Accuracy and precision within ± 20% for LLOQ and ±
15% for other samples of their nominal concentration was considered acceptable.

Recovery
Extraction recovery of target analytes from cell lysate at low, mid and high QC levels was
assessed by comparing extracted analytes responses (pre-extracted spiked samples) to
analytes responses spiked into extracted blank cell extract samples (post-spiked
samples) which was considered 100% recovery.
Post-Extraction Addition experiment (Matrix Factor)
Matrix Factor was evaluated by comparing analytes responses spiked into extracted
blank cell lysate samples (post-spiked samples) to analyte responses in an external
solvent (water).
Stability Studies
Post-preparative extract stability was evaluated at low and high QC levels. QC samples
were processed with a calibration curve and stored in the autosampler at 4°C for seven
days, then re-analyzed and processed against fresh extracted calibration curve, Analyte
stability in frozen matrix was determined by analyzing three replicates of low QC and high
QC samples that had been stored at -80°C for 120 days. For all stability experiments;
precision and accuracy should be within ± 15%.
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Application of the validated method
The hCMEC/D3, cells were grown on 6-well plates. At 90% confluency, the cells were
washed thrice with 1.0 mL Hank’s balanced salt solution (HBSS). The cells were treated
with individual drug solutions of tenofovir, emtricitabine, or dolutegravir. Each drug was
prepared in a 100 mM stock solution in water except dolutegravir, which was diluted in
DMSO. All subsequent working solutions were made in water, and the final concentration
of DMSO for dolutegravir was less than 0.1%. The final treatment concentrations for each
drug were 1436 ng/mL, 1236 ng/mL, 2097 ng/mL (all corresponding to 5 µM) and 2871
ng/mL, 2473 ng/mL, 4194 ng/mL (corresponding to 10 µM), respectively. Additionally,
cells were also treated with two different combinations of tenofovir, emtricitabine, and
dolutegravir in the same incubation solution. In the first combination antiretroviral solution,
all antiretrovirals were at a final concentration of 5 µM, and in the second combination,
all antiretrovirals were at a final concentration of 10 µM. The concentrations used in these
studies were based on the maximum serum concentration (Cmax) of drug obtained from
clinical studies (246–248). Each treatment group was incubated for one hour before
harvest and sample preparation. Upon harvest, the antiretroviral-containing incubation
solutions were removed from each well and cells were quickly washed three times with
1.0 mL of ice-cold HBSS. Cells were lysed by adding 1.0 mL of methanol to the cells,
which was allowed to sit on ice for 15 minutes. Cell extract was collected by scraping the
cells with a cell scraper. Two hundred microliters of the extract were collected in a 96-well
plate, and post-processing of the extract was similar as mentioned in sample preparation.
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The cell lysate was used to calculate protein concentration by Pierce™ BCA protein
assay. Intracellular drug accumulation was expressed as the amount of drug accumulated
per µg of total protein per hour.
Software
Analyst® was used to process data collected from mass-spectrometer. Statistical
analyses were performed using GraphPad Prism (V7) (San Diego, California)

RESULTS
Linearity
Linearity was obtained over a concentration range of 0.100-100 ng/mL for all analytes;
The average correlation coefficient (r2) from five validation runs weighted by 1/x2 was
found to be 0.996 (0.172 %RSD), 0.994 (0.145 %RSD), 0.994 (0.124 %RSD) for
tenofovir, emtricitabine and dolutegravir, respectively. Precision (%RSD) of backcalculated standards were within 9.29%, 10.4 %, and 13.07% for tenofovir, emtricitabine
and dolutegravir, respectively and accuracy (%DFN) were within ±5.43%, ±11.81%,
±2.39% for tenofovir, emtricitabine and dolutegravir, respectively.
Selectivity
Six separate isolations of blank cell lysate collected from passages 26-32 of hCMEC/D3
cells were extracted according to the sample preparation procedure for any potential
interferences at the mass transitions and expected retention times of target analytes. No
significant chromatographic peak greater than 20% of the mean LOQ response was
detected for all analytes.
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Accuracy and precision
Inter-day precision and accuracy were found to be within ± 11.69% (Table 6). Intra-day
precision and accuracy were within ± 13.33% (Table 7) for all analytes.

Table 6: Inter-day accuracy and precision (n=15)

Tenofovir
Emtricitabine
Dolutegravir

0.3
ng/mL

1.0
ng/mL

2.0
ng/mL

50
ng/mL

75
ng/mL

%RSD

7.25

6.33

7.68

10.36

6.77

%DFN

1.64

1.29

4.38

3.33

0.52

%RSD

6.73

3.84

3.06

3.67

8.13

%DFN

7.12

4.90

7.25

3.11

8.27

%RSD

11.69

6.61

6.47

6.83

5.11

%DFN

-0.19

2.05

3.93

6.44

3.19

%RSD = Percent Relative Standard Deviation, %DFN = Percent Difference From Nominal
concentration

Table 7: Intra-day accuracy and precision (n=6)

Tenofovir
Emtricitabine
Dolutegravir

0.1
ng/mL

0.3
ng/mL

1.0
ng/mL

2.0
ng/mL

50.0
ng/mL

75.0
ng/mL

%RSD

13.13

5.53

5.65

5.70

2.45

4.02

%DFN

5.00

3.89

-6.80

2.17

4.30

1.46

%RSD

4.56

5.75

2.32

1.87

2.41

3.77

%DFN

13.33

10.00

3.60

2.75

-1.80

-10.57

%RSD

9.08

7.89

2.98

1.96

1.72

5.73

%DFN

8.33

0.00

-8.00

-4.50

1.67

-4.07

%RSD = Percent Relative Standard Deviation, %DFN = Percent Difference From Nominal
concentration

Dilution integrity
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The intra-assay precision and accuracy were within 9.00% and ± 3.90%, respectively, for
diluted QC samples for all analytes.

Extraction recovery
Extraction recoveries of all analytes from cell lysate were calculated by comparing preextraction spiked samples and post-extraction spiked samples at 2.0, 50 and 75 ng/mL
(n=3). Extraction recoveries for tenofovir, emtricitabine, and dolutegravir were found to be
consistent across different concentration levels; 84.89 (1.18 %RSD), 86.76 (2.50 %RSD),
and 87.33 (3.86 %RSD), respectively.
Matrix Factor
Post-extraction addition experiment was conducted to evaluate matrix effects at 2.0, 50
and 75 ng/mL; by comparing post-extraction spiked matrix samples to matrix freesamples prepared at the same concentrations. Results showed that matrix effects were
within 88.82 (4.88 %RSD), 100.16 (3.09 %RSD), and 104.64 (2.52 (%RSD) for tenofovir,
emtricitabine, and dolutegravir, respectively.
Stability studies
All stability studies showed results within ± 15%; post-preparative extract stability was
found to be stable for seven days at 2-8 °C, and long-term matrix stability was
demonstrated for 120 days at -80 °C.
Application of the method
Tenofovir, emtricitabine, and dolutegravir were incubated individually and together as a
cocktail at both 5 µM and 10 µM for one hour at 37°C to allow time for drug uptake into
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the cells. Following the one hour incubation, the intracellular concentrations of each drug
within the cells was measured using the LC-MS above/MS method. Amount of drug
accumulated with the cells was normalized by the protein content of each well. We were
able to quantify tenofovir, emtricitabine and dolutegravir in the cell lysate of hCMEC/D3
cells treated antiretroviral drugs treated individually and in within a commonly clinically
used cART cocktail (Figure 10). Individual drug and cocktail concentrations were used at
both 5 µM and 10 µM (Table 8). Intracellular concentrations of tenofovir, emtricitabine,
and dolutegravir were determined in hCMEC/D3 using this method.
DISCUSSION
Although several methods have been developed to determine antiretroviral drugs
individually or simultaneously in human plasma or peripheral blood mononuclear cells
(PBMCs), to our knowledge this is the first reported method to simultaneously determine
the regimen tenofovir, emtricitabine, dolutegravir within brain cells. Prathipathi et al.
determined this regimen along with elvitegravir and rilpivirine in mouse plasma, however,
they also did not analyze this regimen in PBMCs or other cellular matrices (243). cART
regimens pose an analytical challenge of determining all the drugs simultaneously due to
the differences in physicochemical properties of the drugs. In the regimen above, NRTIs
(tenofovir, emtricitabine) are hydrophilic, while dolutegravir is lipophilic (222).
A simple extraction procedure involving protein precipitation using 100% methanol was
applied. Raw cell extract was centrifuged, the cell pellet utilized for protein assay, and the
supernatant was processed further for LC-MS/MS analysis (Refer to 2.8).

Several

analytical columns were used to optimize target analytes separation including: X bridge®
(C18, 50 X 2.1mm, 5 µM), Phenomenax® (C18, 50 X 2.1mm., 5 µM), Atlantis® (C18, 50
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X 2.1mm., 5 µM), Acquity (UPLC® BEH C18 50 x 2.1 mm, 1.7 µm). These columns were
compared in terms of peak shape and resolution. X-bridge® (C18, 50 X 2.1mm, 5 µM)
demonstrated excellent peak shape and chromatographic resolution for all analytes
(Figure 2). Sub-2 µm UPLC columns are known to provide better separation. However,
high back-pressure is the main disadvantage of this column, and no superior benefits
were observed with the UPLC column compared to the 5 µm C18 column. Several solvent
system combinations including water, methanol, and acetonitrile with 0.1% formic acid
were attempted. The best peak shape for all analytes was observed with a slow gradient
using water (as mobile phase A) and 0.1% formic acid in acetonitrile (as mobile phase B).
Room temperature and elevated column temperatures were also tested, and room
temperature was found to be convenient for this separation. Several autosampler rinse
solutions were evaluated to eliminate any assay-related carryover (especially for
dolutegravir). Different combinations of methanol, ethanol, isopropanol with water and
formic acid were evaluated; 90:10:0.5 (v/v/v) of ethanol/water/formic acid was the
autosampler rinse solution that eliminated carryover and was chosen for the final method.

Our newly developed method was applied to measure intracellular concentrations of
tenofovir, emtricitabine, and dolutegravir in a human brain endothelial cell line
(hCMEC/D3). We were able to quantify the concentrations of tenofovir, emtricitabine, and
dolutegravir in the hCMEC/D3 cells. Rank order for the accumulation of each drug inside
the hCMEC/D3 cells was dolutegravir > emtricitabine > tenofovir. This pattern can be
explained by physicochemical properties of each drug. Poor accumulation of tenofovir is
explained by its dianionic form at physiological pH responsible for poor bioavailability, and
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activity against HIV-1 in a cell-based assay (249). Emtricitabine is a polar moiety with a
LogP value of -1.40, making it less permeable inside the cells (222). Dolutegravir is
sufficiently lipophilic with a LogP value of 1.10, thus potentially providing a rationale for
why it had the highest accumulation among these drugs (222).
Furthermore, drug accumulation inside cells can be influenced significantly by uptake and
efflux transporters. The two uptake transporters that are known to mediate tenofovir entry
into cells; the organic anion transport proteins 1 and 3 (OAT1; SLC22A6 and OAT3;
SLC22A8, respectively). Although OAT3 is known to be expressed at the human BBB,
neither OAT1 nor OAT3 are expressed by the hCMEC/D3 cells (38, 250). This could be
an explanation for the low intracellular concentrations of tenofovir within these cells.
Tenofovir is also a substrate of the efflux transporter multidrug resistant protein-4 (MRP4; ABCC4), which could further limit intracellular tenofovir concentrations by extruding the
drug from the cell (38). hCMEC/D3 cells are reported to have a similar expression level
of MRP-4 as that in isolated human brain microvessels (133) and therefore MRP-4 may
be further limiting the overall accumulation of tenofovir within hCMEC/D3 cells.
Emtricitabine is a substrate of the uptake transporter, multidrug and toxin extrusion
protein-1 (MATE1: SLC47A1), however, they were found at a low level in hCMEC/D3 cells
(133). Dolutegravir is the substrate of P-glycoprotein (P-gp; ABCB1) and breast cancer
resistant protein (BCRP; ABCG2), both of these transporters are expressed and
functional in hCMEC/D3 cells and limits intracellular accumulation (42). However,
experimental manipulation of these potential interactions of drugs and uptake/efflux
transporters was beyond the scope of this study. Finally, this method was successfully
applied to estimate intracellular concentrations of tenofovir, emtricitabine and dolutegravir
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in endothelial cells (hCMEC/D3). Besides endothelial cells, HIV-1 infects astrocytes,
microglia, and pericytes in the CNS. Intracellular concentration of antiretroviral drugs
within these cell types are scantly reported in the literature, but it may be important to
ascertain anti-HIV-1 activity of the drugs inside each CNS cell type. Thus, future studies
will be done to assess intracellular antiretroviral concentrations in human pericytes,
human astrocytes, and human microglia.
In this study, we developed a bioanalytical assay with high sensitivity and specificity to
simultaneously measure tenofovir, emtricitabine, and dolutegravir in cell extracts of
hCMEC/D3 cells. The method was successfully validated according to FDA guidance and
applied to determine uptake of tenofovir, emtricitabine, and dolutegravir inside
hCMEC/D3 cells.
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Table 8: Intracellular accumulation of antiretroviral drugs/ treatment regimen
Treatments
Concentration
Drugs

5µM

10µM

5µM

10µM

5µM

10µM

Picomoles/mg
of protein

Picomoles/mg
of protein

Conc.
(ng/mL)

Conc.
(ng/mL)

Protein
Conc.
(mg/mL)

Protein
Conc.
(mg/mL)

5.91 ± 1.74

5.32 ± 1.07

0.32 ± 0.08

0.64 ± 0.17

0.22 ± 0.08

0.42 ± 0.07

Emtricitabine

19.74 ± 3.13

16.95 ± 4.66

1.18 ± 0.10

2.44 ± 0.44

0.26 ± 0.05

0.47 ± 0.08

Dolutegravir

74.84 ± 9.84

250.49 ± 45.45

14.19 ± 0.62

48.57 ± 5.04

0.46 ± 0.05

0.48 ± 0.06

Tenofovir

2.63 ± 0.86

5.15 ± 1.11

0.32 ± 0.07

0.64 ± 0.15

0.46 ± 0.06

0.43 ± 0.06

Emtricitabine

9.29 ± 1.89

23.36 ± 4.56

1.01 ± 0.11

2.40 ± 0.21

0.46 ± 0.06

0.43 ± 0.06

Dolutegravir

81.09 ± 18.51

266.90 ± 40.99

14.67 ± 1.41

46.63 ± 2.71

0.46 ± 0.06

0.43 ± 0.06

Individual Drugs
Tenofovir

Drugs in
combination

Intracellular accumulation of each antiretroviral drug in the brain endothelial cell line, hCMEC/D3 cells. hCMEC/D3 cells were incubated
with 5 or 10µM of dolutegravir, emtricitabine, or tenofovir or the cocktail of 5 or 10 µM of each drug given as a three-drug combination
(cART). Data are expressed as mean ± SEM (For drug accumulation in picomoles/µg of protein, and ng/mL, the protein concentration
in µg/mL) for n=3 independent experiments.
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A

B

C

Figure 10: LC-MS/MS
chromatograms of (A) Blank cell
lysate matrix, (B) Blank cell lysate
D

matrix spiked with labeled internal
standards (Tenofovir-d6,
Emtricitabine-13C6, 15N2 and
Dolutegravir-d5) and (C) 0.1 ng/mL
(LLOQ) of Tenofovir, Emtricitabine
and Dolutegravir (D) intracellular
accumulation inside hCMEC/D3
samples
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Effect of HIV-1 Tat and Morphine on antiretroviral penetration in different CNS cell
types

Introduction
In 2016, approximately 36.7 million people are living with HIV (9). Nearly half of the HIVinfected individuals experience HIV-associated neurocognitive disorder (HAND) (218,
251). Clinical presentation of HAND can range from severe (HIV-Associated Dementia)
to mild neurocognitive disorder (MND) or asymptomatic neurocognitive impairment (ANI)
(252). Substance abuse and HIV are interlinked epidemics, and substance abuse is also
one of the significant comorbidities in HAND (253). Heroin (an opioid) is one of the most
commonly used illicit drugs in HIV patients, and it is one of the major drugs of abuse in
Injection Drug users (IDUs) (254, 255). Recently, prescription opioid abuse through
injection had led to outbreaks of HIV (10). Opioid abuse worsens HIV progression by
effecting host immune functions causing opportunistic infections (256), increasing virus
entry into immune cells and replication therein (257), increases trafficking of infected
immune cells into CNS (257). CNS infection of HIV causes immune activation of
microglia, astrocytosis, and chronic inflammation, which are hallmarks of the
neuropathogenesis of HAND (258, 259).
Despite aggressive use of cART (combination antiretroviral therapy), HIV viral loads
persist in the central nervous system (CNS) (as measured in cerebrospinal fluid (CSF))
and prevalence of mild to moderate neurocognitive impairment continues even after many
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years of suppressive therapy (60, 222, 260–262). Persistence of viral loads (as measured
from CSF) in CNS despite the use of cART, the CNS is a sanctuary for the virus and
latent infection in CNS (221, 263, 264). Viral persistence within the CNS suggests that
the concentrations of antiretroviral drugs inside the brain are sub-therapeutic, resulting in
low level of ongoing replication of the virus in the CNS. The viral proteins released from
infected cells cause chronic inflammation, leading to the development of HAND (158,
265, 266). Patients on cART regimens with high CNS penetration effectiveness (CPE)
have reduced viral loads in the CNS (as measured in CSF), but the correlation between
CPE and clinical outcomes in HAND is not clearly understood (261, 267). Since most
antiretroviral drugs (protease inhibitors, nucleoside reverse transcriptase inhibitors
(NRTI), and integrase strand transfer inhibitors (INSTI), have their targets located inside
the host cell; intracellular concentrations are key in determining the efficacy of
antiretroviral drugs (222).
HIV-1 Tat (Transactivator of Transcription) is a regulatory protein, which induces HIV-1
gene expression during transcription initiation and elongation. Cells infected by HIV-1
secrete HIV-1 Tat, which then easily permeates into other cells, including neurons,
through adsorptive endocytosis, affecting the viability and functions of neurons (43). Tat
causes direct neurotoxicity through an increase in intracellular calcium resulting in
excitotoxic damage (268), caspase activation leading to apoptosis (269), and release of
proinflammatory cytokines (270). Infected monocytes and perivascular macrophages
predominantly seed HIV infection in CNS (271, 272), releasing the virus and viral proteins
(including HIV-1 Tat), which in turn activates glial cells (uninfected and infected). The
activated glial cells then release inflammatory cytokines (59, 273, 274), increase
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glutamate release (275), and cause neuronal dysfunction and death. HIV-1 Tat
upregulates P-gp (P-glycoprotein) expression and activity (276), which is responsible for
efflux of antiretroviral drugs at the blood-brain barrier (223). Opioids, especially, morphine
produces a robust inflammatory response in the CNS, on top of already existing
inflammation due to HIV-1 infections, exacerbating HAND. Morphine disrupts blood-brain
barrier resulting in trafficking of infected immune cells in the brain (119), increases
expression of chemokine receptors on microglia and astrocytes (277, 278), promotes the
release of pro-inflammatory cytokines from glial cells (85, 253), and causes neurotoxicity.
Morphine is a substrate of P-gp, and it is known to induce expression of P-gp, which
reduces penetration of antiretroviral drugs that are substrate of P-gp (279–281).

Co-

exposure of morphine and Tat synergistically increases blood-brain barrier (BBB)
permeability (106), increases caspase-3 activity leading to apoptosis in murine
oligodendrocytes (282), upregulates pro-inflammatory cytokines in CNS cell types
(human astrocytes, microglia, and brain microvascular endothelial cells) (119, 283, 284),
and increases microglial activation and migration. These events cause chronic
inflammation, which affects neural function and viability underlying HAND. Interactive
effects of HIV-1 Tat and morphine may alter antiretroviral drug penetration in HIV infected
CNS cells via efflux or uptake transporters, leading to sub-therapeutic concentrations of
antiretroviral drugs in the brain. However, the effects of Tat and morphine on antiretroviral
drug penetration inside CNS cell types have not been substantially investigated in the
current literature.
In this study, we measured drug concentration in primary human brain microvascular
endothelial cells, human astrocytes, human microglia, human pericytes, and immortalized
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human cerebral microvascular endothelial cells (hCMEC/D3). Each of these cell types
has a distinct role in the neuropathogenesis of HAND, namely, human brain
microvascular endothelial cells (HBMEC) line the small cerebral vessels forming the
Blood-Brain Barrier (BBB), through which free virus or virus-infected monocytes enter
CNS (285). The BBB also restricts the entry of xenobiotics, including antiretroviral drugs,
into the brain via tight junctions and drug transporters (efflux and uptake). Inside the CNS,
productive replication of virus occurs in perivascular macrophages and microglia, while
astrocytes, pericytes, and brain microvascular endothelial cells are sites of nonproductive replication of the virus. Pericytes, astrocytes, brain microvascular endothelial
cells, are part of neurovascular Unit (NVU). Pericytes wrap around small cerebral vessels
and are responsible for differentiation (286) and stabilization of capillaries (287), and
maintenance of BBB (288, 289). HIV infection in pericytes causes the release of
inflammatory cytokines, disrupts BBB, increasing the flux of virus in the brain (231).
Astrocytes are also part of the NVU and are responsible for maintenance of the BBB
through the release of several factors like sonic hedge hog (shh) (290), basic fibroblast
growth factor and angiopoietin-1 (291), and glial-derived neurotrophic factor (GNDF)
(292). HAND is mediated-glially due to the presence of all types of glial cells (astroglia,
microglia, oligodendroglia, and ependymal cells) throughout CNS (117).

Also, glia

(infected and uninfected) are responsible for neuronal injury and death of through the
release of inflammatory cytokines and neurotoxins.
There is evidence of differential efficacy of the antiretroviral drug in different cell types.
Asachop et al. reported the lower intracellular concentrations of antiretroviral drugs in
human microglia when compared to human lymphocytes, resulting in significantly higher
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EC50 values in human microglia (237). Similarly, Gray et al. demonstrated that
antiretroviral drugs have significantly lower efficacy in CNS cell types when compared to
peripheral mononuclear blood cells and monocyte-derived macrophages (131). This
evidence suggests that the efficacy of antiretroviral drug significantly changes in different
cell types, which may be mediated by differential accumulation of drugs into these cells.
However, intracellular accumulation of antiretroviral drugs within different brain cell types
in the setting of HIV and drug abuse is scantly reported in the current literature. To
address this gap, we hypothesize there is differential intracellular penetration of the cART
regimen consisting of tenofovir, emtricitabine, and dolutegravir (a regimen recommended
by recent guidelines issued by Department of Health Human Services (239)), in different
CNS cell types (primary HBMECs, astrocytes, microglia, pericytes, and the immortalized
cell line, hCMEC/D3), when treated with HIV-1 Tat and/or morphine.

Methods
Chemical and reagents

The following reagents were obtained through the NIH AIDS Reagent Program, Division
of AIDS, NIAID, NIH: Tenofovir, Emtricitabine [(-) FTC], Dolutegravir. Tenofovir-d6 and
emtricitabine-13C 15N2 were obtained from Toronto Research Chemical Inc. (Ontario,
Canada). Dolutegravir-d5 was purchased from BDG Synthesis (Wellington, NZ).
Methanol, acetonitrile with 0.1% formic acid, 2-propanol (HPLC grade) was obtained from
Honeywell Chemicals (Muskee, MI). 6-well plates were used from Corning Inc. (Corning,
NY, USA). Human brain microvascular endothelial cells, hCMEC/D3, were generously
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provided by Dr. Babette Weksler of Weill Cornell Medical College, Cornell University (New
York, NY). Endothelial basal media (EBM-2) and the EGM2-MV Bullet kit were purchased
from Lonza (Basel, Switzerland). The EGM2-MV Bullet kit contained human endothelial
growth factor (hEGF), insulin-like growth factor (IGF), human fibroblast growth factor
(hFGF), vascular endothelial growth factor (VEGF), hydrocortisone, ascorbic acid, FBS,
GA-1000 (gentamycin and amphotericin). 0.45 µm multiscreen HTS filter plate was
purchased from Millipore (Millipore sigma, USA). Primary Human pericytes and
astrocytes, along with pericyte and astrocyte medium was purchased from Science Cell,
Inc., (Carlsbad, CA). Primary human microglial cells and primary human microglial
complete serum media were obtained from Celprogen, Inc. (Torrance, CA). Primary
human brain endothelial cells, complete classic basal media, cultureboost™, Passage
reagent Group 1,2,3 (PRG®), were purchased from Cell Systems, Inc. (Kirkland, WA).
Recombinant HIV-1 Tat was obtained from ImmunoDx, Inc. (Woburn, MA). Ultrapure™
water was obtained from Quality Biologicals, Inc. (Gaithersburg, MD). GIBCO® Hanks
Balanced Salt Solution (HBSS), Rat Tail Collagen Type 4, Pierce BCA Protein Assay kit
were obtained from Thermo Fisher Scientific, Inc. (Waltham, MA).

Cell Culture
hCMEC/D3 were grown in EBM-2 media supplemented with EGM2-MV bullet kit at 5%
CO2, 37°C and 95% relative humidity (termed growth medium). Cells seeded on 6-well
plate were grown on EBM-2 media supplemented with 1.25% FBS, 5 mL of
penicillin/streptomycin solution (10,000 U/mL), 5 mL of 10 mM HEPES and 1.25 ml of 0.5
ng/mL bFGF (termed maintenance medium). Primary human astrocytes were grown in
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astrocyte medium consisting of 500 mL of basal media, 10 mL of FBS, 10 mL of astrocyte
growth supplement, and 5 mL of penicillin/streptomycin solution at 5% CO2, 37°C and
95% relative humidity. Cells were used from passage 8-13. Primary human pericytes
were grown in pericyte medium consisting of 500 mL of basal media, 10 mL of FBS, 10
mL of pericyte growth supplement, and 5 mL of penicillin/streptomycin solution at 5%
CO2, 37°C and 95% relative humidity. Cells were used up to 10 passages. Primary human
microglia was grown in primary human microglia complete growth media with serum at
5% CO2, 37°C and 95% relative humidity. Cells were propagated from passage 2 to
passage 10.
Primary human astrocytes, pericytes, and microglia were seeded on T75 flasks and 6well plate pre-coated with 0.5 mg/mL of poly-L-Lysine in 0.1 M sodium borate buffer at
pH 8.4. hCMEC/D3 cells were plated on collagen-coated T75 flasks, and 6-well plate
coated. With 0.15 mg/mL of Rat Tail Collagen IV solution overnight and washes three
times with D-PBS (Dulbecco’s Phosphate buffer solution). Primary human microvascular
endothelial cells were coated with Attachment Factor™ for 5s and aspirated before
seeding. These cells were grown in complete classic basal media supplemented by
CultureBoost™until passage 7-9. Passage reagent Group 1,2,3 (PRG®) from Cell
Systems, Inc., were used for subculturing and passaging.
Treatment
When cells reached 90% confluency, they were treated with Tat (100nM) and morphine
(500 nM) for 24 h. A stock solution of HIV-1 Tat and Morphine were made in ultra pure
water. After 24 h, antiretroviral accumulation over 1 h was measured. Stock drug
concentration for tenofovir and emtricitabine were prepared in water at 5 mM and 10 mM,
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while dolutegravir was prepared in 100 mM stock in DMSO. The final concentration of
working stock solution was made to 5 µM, and 10 µM for each drug in water, the final
concentration of DMSO were less than 0.01% in final working working solution.
Concentrations of drugs were decided based on Cmax of the drug in clinical trials (246–
248, 293). Experiments were performed in two designs. In the first design, treatment
includes only antiretroviral drugs, where each cell type was treated with an individual drug
(tenofovir, emtricitabine, dolutegravir) and combined ARV (all together) at 5 µM and 10
µM for 1 hour at 37°C at 5% CO2. This experimental design had no HIV-1 Tat and
morphine treatment. In the second experimental design, each cell type was treated with
HIV-1 Tat, morphine, and Tat + morphine for 24 h, and then treated with combined ARV
at 5 µM and 10 µM for 1 h.
Intracellular accumulation of antiretroviral drugs
Each cell type was allowed to grow to 90% confluency on six-well plates. At the end of
treatments (described above) for each experimental design, cells were washed thrice with
1 mL of ice-cold HBSS. Then 1 mL of ice-cold methanol was added on each well of the
plate and allowed to sit on the ice for 15 minutes. Methanolic cell extract was prepared
by thoroughly scrapping the cells with scrapper on ice. The resultant solution was
collected and centrifuged at 7500 rpm. 200 µL of supernatant from each sample was
aliquoted into a 96-well plate, and 20 µL of 50 ng/mL is working internal standard solution
was added. Samples were vortex mixed for 5.0 minutes at 750 rpm and centrifuged for
15 minutes at 5000 rpm. 150 µL of supernatant was collected, filtered through a 0.45 µm
multiscreen HTS filter plate (centrifuged for 5 min at 3500 rpm) and dried under a steady
stream of nitrogen at 45°C. The dried extracts were reconstituted with 150 µL of water,
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mixed for 10 minutes at 5000 rpm and re-centrifuged again for 15 minutes at 5000 rpm.
50 µL of the final extract was injected for LC-MS/MS analysis (refer Chapter 3). The pellet
containing cell debris was incubated with 50 µl lysis buffer (NP40+complete protease
inhibitor) for 5 minutes on ice. Cell pellets containing lysis buffer were sonicated and
analyzed for protein content using the BCA Protein Assay.
Statistical Analysis

Two way ANOVA with Tukey's post hoc test was used for all the analyses. A p value
less than or equal to 0.05 was considered statistically significant. GraphPad Prism
Software (San Diego, California) was used for statistical analyses.
Results
Intracellular accumulation of individual and combined antiretroviral drugs in
untreated CNS cell types

To determine differential accumulation of antiretroviral drugs in primary human brain
endothelial cells, primary human astrocytes, primary human pericytes and immortalized
human brain microvascular endothelial cells (hCMEC/D3), each cell type was treated with
tenofovir, emtricitabine and dolutegravir individually and in a three-drug combination at
both 5 µM and 10 µM for 1 h. In all the cell types, intracellular accumulation in
(picomoles/µg of protein) was in the following order: dolutegravir > emtricitabine >
tenofovir (Table 9). This trend was consistent when cells were treated both as individual
agents and also in when given in a combination of antiretroviral drugs, at both
concentrations. hCMEC/D3 cells had a significantly higher accumulation of tenofovir
(p=0.00001), emtricitabine (p=2.89e-08) in comparison with other cell types that were
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treated either individually or in a combination of antiretroviral drugs. Intracellular
accumulation of dolutegravir was higher in hCMEC/D3 than other cell types, but it was
not statistically significant (p=0.0767) (Table 9). The intracellular concentrations of each
drug (given as individual drug or in combination) were significantly higher for the
concentration of 10 µM as compared to 5 µM for emtricitabine (p=0.0001) and dolutegravir
(p=8.88e-7), as would be expected. However, the intracellular concentration of tenofovir
were higher at 5 µM than 10 µM, although this did not reach statistically significance
(p=0.0867) (Table 9). Intracellular accumlation at a loading concentration of 10 µM would
be double that of 5 µM provided there is a linear relationship between drug accumulation
and loading dose. Experimentally, such relationships were not observed and may be due
to the involvement of drug transporters (uptake or efflux), whose activities might become
saturated above a certain concentration. Overall, these results demonstrate that
intracellular accumulation of tenofovir, and emtricitabine either individually or in
combination, was signficantly higher in hCMEC/D3 (immortalized cell line) than primary
cell types. The trend for intracellular concentration across all cell types, and loading
concentrations was of dolutegravir > emtricitabine > tenofovir.

Intracellular accumulation of combined antiretroviral drugs in CNS cell types
treated with HIV-1 Tat and/or morphine
Intracellular accumulation of combined antiretroviral drugs at loading concentrations of 5
µM and 10 µM were estimated in all the cell types after exposure with 100 nM of Tat
and/or 500 nM of morphine for 24 h. Consistent with trends from intracellular
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accumulation in untreated cells, the rank order of intracellular accumulation was
dolutegravir > emtricitabine > tenofovir. Intracellular accumulation of antiretroviral drugs
treated with loading concentration of 5 µM was significantly different than with 10 µM
loading concentration in all the cell types, with the treatment of Tat and morphine (Table
10 A, B, C). There were no significant differences in intracellular accumulation of
antiretroviral drugs after treatment with Tat and morphine in any of the cell types tested
(Table 10 A, B, C).

Discussion

The antiretroviral regimen comprised of tenofovir, emtricitabine and dolutegravir is one of
the recommended regimens from Department of Health and Human Services for
treatment of both for adult and adolescent patients infected by HIV (294). Currently, this
treatment regimen is being used in several randomized clinical trials, namely, DOLPHIN1
and VESTED - evaluating efficacy in pregnant women, INSPIRING – evaluating efficacy
in opportunistic TB infection, ADVANCE – evaluating efficacy for the first line of treatment
(295). Once-daily dosing and greater half-life in tissue than in plasma make it preferred
regimen for HIV-1 infection (296). Passage of these drugs into the brain is restricted by
the BBB, because of their physicochemical properties and because these ARVs are
substrate for efflux transporters located on the luminal side of blood-brain barrier. Poor
penetration of these drugs into the brain is believed to one of the reasons for viral
persistence inside the brain (297).
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The questions addressed by the present study were (1) is there a differential
accumulation of antiretroviral drugs, individually and in combination, in different CNS cell
types and, (2) is there a differential accumulation of combined antiretroviral drugs in
different CNS cell types when treated with HIV-1 Tat and/or morphine. Our results
indicated that intracellular accumulation of tenofovir, emtricitabine, and dolutegravir,
individually or in combination at a loading concentration of 5 µM and 10 µM in untreated
cells, was significantly higher in hCMEC/D3 cell line (immortalized) when compared to
the other primary cells from the CNS. There were also no significant changes in ARV
accumulation upon exposure to Tat and/or morphine within the different CNS cell types.
Overall, the trends of intracellular antiretroviral drug accumulation in untreated or treated
cells, either individually or in combination, at a loading concentration of 5 µM and 10 µM,
was found to be dolutegravir > emtricitabine > tenofovir. Rimawi et al. investigated
penetration of these same antiretroviral drugs (tenofovir, emtricitabine, and dolutegravir)
through the placental barrier and observed similar trends in intracellular accumulation of
these ARVS within placental tissue (298). The study reported herein is, to our knowledge,
the first to determine intracellular concentrations of two NRTI (tenofovir and emtricitabine)
and an INSTI (dolutegravir) in different CNS cell types.
We wanted to determine intracellular accumulation of antiretroviral drugs, both
individually and in combination at clinically relevant concentrations (5 µM and 10 µM) in
different CNS cell types. The results demonstrate that, irrespective of whether the
antiretroviral drugs were dosed individually or in combination, there was a significantly
higher accumulation of tenofovir and emtricitabine within hCMEC/D3 cells when
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compared to the accumulation within the other cell CNS types. Dolutegravir intracellular
concentrations, however, were not significant in hCMEC/D3 compared to other cell types.
The result observed herein may be attributed to differences in physicochemical properties
of each drug, as well as the affinity for, and activity of, uptake and efflux transporters
within each cell type. For example, tenofovir is a substrate of the uptake transporters
OAT1, OAT3, and the efflux transporter MRP-4 (38). OAT1 and OAT3 have been
detected at low levels in hCMEC/D3 cells (133); while in primary human microvascular
brain endothelial cells only OAT3 is expressed (134). Furthermore, OAT1 and OAT3 are
absent in glial cells or pericytes (140). These transporter expression patterns are
consistent with the observed findings of higher accumulation of tenofovir in hCMEC/D3
cells compared to other cell types.
Furthermore, MRP4, which is responsible for efflux of tenofovir out of the cell, is
expressed in hCMEC/D3 (133), primary brain endothelial cells (299), astrocytes (137) but
not reported to be present in pericytes or microglia (142, 135). Emtricitabine is a substrate
of the MATE1 (Multidrug and Toxic Compound Extrusion1) transporter (39), which is
responsible for extruding drug outside the cell and is not expressed in hCMEC/D3 (133,
300), and expressed in primary brain microvessels (301), and there is no evidence in
current literature for its presence in glia or pericytes. MATE1 expression profiles might
explain the significant accumulation of emtricitabine in hCMEC/D3 cells when compared
to primary brain microvascular endothelial cells. Dolutegravir is a substrate of P-gp and
BCRP; however, cellular accumulation of dolutegravir in hCMEC/D3 cells was not
significantly different when compared to other primary CNS cell types. hCMEC/D3 is an
immortalized cell line derived from human brain microvascular endothelial cells that might
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have different genotypic and phenotypic features than primary cells. This difference might
explain the significantly higher intracellular accumulation of antiretroviral drugs in
hCMEC/D3 cells compared to primary cells. hCMEC/D3 cells are routinely employed in
BBB studies because primary human brain microvascular endothelial cells are difficult
and costly to acquire (302). However, variations caused by the immortalization process
to generate hCMEC/D3 might result in differences in protein expression between the
immortalized cell and the primary brain endothelial cells.
We aimed to determine the effects of Tat and/or morphine on combined antiretroviral
penetration inside these CNS cell types. Contrary to our hypothesis, we found that
exposure of Tat and/or morphine had no significant effect on the intracellular
accumulation of antiretroviral drugs. The treatment time point of 24 h was based on proinflammatory cytokines released from cells on exposure with Tat and morphine from
previous studies (85, 119). These inflammatory cytokines regulate expression of drug
transporters, (180, 303–305) which, in turn, may affect intracellular drug accumulation.
Future studies including concentration and time-dependent effects of Tat and/or morphine
on the release of pro-inflammatory cytokines from each of the cell type will thoroughly
investigate treatment effects on intracellular accumulation, and significant changes if any.
Antiretroviral drugs were incubated for 1 h based in order to achieve quantifiable
concentrations intracellularly. Also, previous studies reported the same period to study
the cellular accumulation of antiretroviral drugs (38, 232).
Moreover, NRTIs need to be converted to their triphosphorylated metabolite to be
pharmacologically active. This intracellular transformation requires about 16-18 h of time
(306). Thus, an expanded time course of intracellular drug accumulation might
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significantly alter the intracellular accumulation of antiretroviral drugs. Bosquet et al. used
20 h incubation of tenofovir, emtricitabine and efavirenz for determining intracellular
accumulation and studying modulation of ABC (ATP Binding Cassette) transporters by
antiretroviral drugs (307). They reported significant differences in accumulation of each
drug within PBMC. Therefore, further studies investigating longer incubation times of
antiretroviral drugs, and concentration and time-dependent studies measuring proinflammatory cytokines, would provide better insights into intracellular drug accumulation.
Our findings show that the overall trend in the rank order of intracellular accumulation of
antiretroviral drug is consistent throughout the study, dolutegravir had the highest
accumulation, while tenofovir had lowest, accumulation, and emtricitabine had
intermediate accumulation. The intracellular accumulation of the antiretroviral drug in all
the cell types was consistent with CNS penetration effectiveness score for each drug,
dolutegravir > emtricitabine > tenofovir (127, 308). Recent reports link dolutegravir with
neuropsychiatric adverse events in different populations (309–311). Our findings report
higher accumulation of dolutegravir in all the cell types after 1-hr of incubation; however,
chronic exposure may lead to higher accumulation inside the cells leading to cellular
toxicity, causing CNS side effects. This trend may be partially explained by the
physicochemical properties of drugs. Dolutegravir has highest due to lipophilicity (log P
1.11) of the drugs tested and, therefore, it would be predicted to have the highest
intracellular accumulation (222). Emtricitabine has a polar moiety, making it less
permeable than dolutegravir, which would limit its penetration into the cells (222). Based
on physicochemical properties, it could be predicted that tenofovir would have the lowest
accumulation because it would be anionic at physiological pH (312). It must be recognized
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that drug accumulation is dependent on more than just its physicochemical properties.
Affinity for, and activity of, uptake and efflux transporters as well as transporter and
metabolism mediated interactions with other drugs, may also modulate intracellular drug
exposure. Some of the aforementioned physicochemical properties are correlated to the
substrate specificity of transporters (313–315). Also, the treatment regimen studied herein
is reported to have limited to no potential drug-drug interactions at drug transporters (316,
317). Expression of transporters in CNS cells is regulated by nuclear receptors (318),
xenobiotic activation of nuclear receptors and subsequent induction of expression of the
transporter is a complex multi-stage process, requiring incubation time of several days
(41). The incubation time of antiretroviral drugs for one hour is likely insufficient to alter
expression of drug transporters. Thus, physiochemical properties, as well as drug
transporter involvment, provides the rationale behind the overall trend in accumulation
amongst three drugs in this study. This accumulation pattern observed in this study is
also reflected in the CNS efficacy of each drug. Protein-free IC50 values of tenofovir,
emtricitabine, and dolutegravir were reported to be 201.6 ng/mL, 70 ng/mL, 0.2 ng/mL,
respectively (222).
In conclusion, our results indicated that Tat and morphine had no significant impact on
the intracellular accumulation of antiretroviral drugs. hCMEC/D3, an immortalized cell line
had significantly higher accumulation of drugs compared to primary cell types.
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Table 9: Intracellular accumulation (picomoles/mg of protein) of 5µM of individual and combined antiretroviral drugs in
untreated cells
5 µM of individual drugs

5 µM of combined drugs

Tenofovir

Emtricitabine

Dolutegravir

Tenofovir

Emtricitabine

Dolutegravir

HBMEC

2.46 ± 1.02

2.84 ± 0.96

33.15 ± 18.26

1.75 ± 0.78

5.32 ± 1.68

39.84 ± 21.81

Microglia

0.75 ± 0.19

5.63 ± 1.54

26.94 ± 7.38

0.50 ± 0.09

4.01 ± 0.58

30.15 ± 11.63

Astrocytes

2.33 ± 0.89

12.88 ± 6.49

37.22 ± 8.40

3.75 ± 0.79

15.67 ± 3.99

68.57 ± 11.33

Pericytes

0.96 ± 0.29

6.79 ± 2.77

32.41 ± 6.69

0.83 ± 0.21

5.34 ± 1.03

28.19 ± 5.18

hCMEC/D3

5.17 ± 0.99

19.50 ± 4.25

79.43 ± 12.14

2.99 ± 0.83

10.14 ± 1.78

77.8 ± 9.73

10 µM of individual drugs

10 µM of combined drugs

Tenofovir

Emtricitabine

Dolutegravir

Tenofovir

Emtricitabine

Dolutegravir

HBMEC

3.99 ± 0.99

8.88 ± 1.94

76.70 ± 21.68

3.16 ± 0.92

7.10 ± 1.67

96.79 ± 24.04

Microglia

1.99 ± 0.35

10.67 ± 2.18

190.29 ± 58.37

1.97 ± 0.44

14.4 ± 4.18

184.31 ± 55.49

Astrocytes

2.94 ± 0.75

17.31 ± 7.50

229.63 ± 87.67

3.22 ± 0.65

17.02 ± 0.59

177.32 ± 48.88

Pericytes

2.40 ± 0.75

9.15 ± 1.48

293.08 ± 91.91

2.30 ± 0.60

11.62 ± 2.28

243.23 ± 62.78

*hCMEC/D3

4.85 ± 0.65

21.04 ± 3.78

277.77 ± 41.74

5.98 ± 0.73

23.70 ± 2.68

278.48 ± 25.16
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Table 9A: Intracellular accumulation (picomoles/µg of protein) of 5µM of individual and combined antiretroviral drugs in untreated cells
Each value of Intracellular accumulation is represented in mean ± SEM of picomoles/ µg of protein. Human cerebral microvascular
endothelial cell line/D3 has significantly higher accumulation for tenofovir and emtricitabine compared to other cell types with individual
drug or in combination, and at either 5 µM or 10µM. Each value represents intracellular accumulation in picomoles/µg of protein
expressed as mean ± SEM for n=6 independent experiments.
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Table 10 A: Intracellular accumulation of tenofovir in picomoles/mg of protein
5 µM of combination antiretroviral drugs

*10 µM of combination antiretroviral drugs

Tenofovir

Control

Tat

Mor

Tat + Mor

Control

Tat

Mor

Tat + Mor

HBMEC

0.69 ± 0.25

0.95 ± 0.23

2.08 ± 1.11

1.16 ± 0.42

1.85 ± 0.33

3.39 ± 0.98

2.87 ± 0.46

1.27 ± 0.64

Microglia

0.65 ± 0.23

0.83 ± 0.23

0.80 ± 0.29

0.69 ± 0.12

1.03 ± 0.12

0.79 ± 0.04

0.93 ± 0.06

0.89 ± 0.16

Astrocytes

2.08 ± 0.59

1.96 ± 0.61

1.43 ± 0.35

1.21 ± 0.20

3.36 ± 1.69

3.93 ± 0.65

3.09 ± 0.33

3.21 ± 0.36

Pericytes

1.08 ± 0.30

0.81 ± 0.18

1.11 ± 0.23

1.46 ± 0.29

2.83 ± 1.07

3.02 ± 1.57

1.59 ± 0.45

1.76 ± 0.51

hCMEC/D3

0.40 ± 0.09

0.24 ± 0.03

0.25 ± 0.03

0.21 ± 0.04

0.82 ± 0.15

0.68 ± 0.10

1.38 ± 0.60

0.86 ± 0.15

Table 10 A: Intracellular accumulation of tenofovir from 5 and 10 µM of combined antiretroviral drugs in different CNS cell
types. Intracellular accumulation is represented as mean ± SEM picomoles/mg of protein for n=6 independent experiments.
There were no statistically significant differences between treatments, however, drug accumulation between 5 µM and 10
µM were significantly different.
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Table 10 B: Intracellular accumulation of emtricitabine in picomoles/mg of protein

Table 10 B: Intracellular accumulation of emtricitabine from 5 and 10 µM of combined antiretroviral drugs in different CNS
cell types. Intracellular accumulation is represented as mean ± SEM picomoles/mg of protein for n=6 independent
experiments. There were no statistically significant differences between treatments.

.
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Table 10 C: Intracellular accumulation of dolutegravir in picomoles/mg of protein in treated cells

Table 10C: Intracellular accumulation of dolutegravir from 5 and 10 µM of combined antiretroviral drugs in different CNS
cell types. Intracellular accumulation is represented as mean ± SEM picomoles/mg of protein for n=6 independent
experiments. There were no statistically significant differences between treatments. however, drug accumulation between
5 µM and 10 µM were significantly different.
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Conclusions & Future Directions
Collectively, our investigations indicate that HIV-1 Tat and methamphetamine alter
aspects of BBB integrity without affecting net flux of paracellular compounds. Tat and
methamphetamine may also affect several aspects of transcellular transport. Tat and
methamphetamine containing treatment inhibited or impaired P-glycoprotein-dependent
rhodamine123 efflux in hCMEC/D3 cells, without affecting P-glycoprotein or MRP-1
protein expression levels. Despite impaired P-glycoprotein dependent transport with Tat
and methamphetamine exposure, atazanavir failed to accumulate within the cells.
Because atazanavir is a substrate for two efflux transporters (P- glycoprotein and MRP1) within the BBB, it is likely that the redundancy allows atazanavir to be shunted through
the opposing transporter when the first is impaired. Indeed, single transporter inhibition
did not result in significant increases in atazanavir accumulation, but simultaneous
inhibition of efflux transporters increased atazanavir accumulation in the BBB cells.
A simple and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS)
method for simultaneous determination of tenofovir, emtricitabine, and dolutegravir in cell
lysates of an immortalized human brain microvascular endothelial cell line (hCMEC/D3)
was developed and validated. Analytes were separated on a reverse phase C18 column
using H2O and acetonitrile with 0.1% formic acid mobile phases. The analytes were
detected using positive electrospray ionization mode with multiple reaction monitoring
(MRM). The assay was linear in the concentration range of 0.1-100 ng/mL for all analytes.
Intra- and inter-assay precision and accuracy were within ± 13.33% and ± 11.69%,
respectively.
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The validated method was applied to determine the intracellular concentrations of the
antiretroviral regimen consisting of tenofovir, emtricitabine, and dolutegravir in five
different brain cell types: primary human brain microvascular endothelial cells, primary
human microglia, primary human astrocytes, primary human pericytes, and the
immortalized brain microvascular endothelial cell line, hCMEC/D3 cells. Intracellular
antiretroviral drug accumulation, either individually or in combination was found to be
significantly higher in hCMEC/D3 cells compared to other cell types. These cells were
treated with Tat and/or morphine. After 24 h, intracellular accumulation was quantified.
No significant differences in antiretroviral drugs accumulation were observed between
treatment groups. Overall, rank-order of intracellular accumulation of antiretroviral drugs
in different CNS cell types in picomoles/µg of protein was found to be dolutegravir >
emtricitabine > tenofovir.
Future studies will include incorporating treatments (Tat and/or Morphine) for the
expanded period, increasing the incubating period of the antiretroviral drugs, and single
round infectivity assays to determine the efficacy of antiretroviral drugs in several cell
types in presence or absence of morphine. Additionally, we plan to develop and validate
the LC-MS/MS method mentioned above in mouse plasma and brain tissue homogenates
of a mouse. This method will be used in studying antiretroviral concentration in different
parts of brains of Tat transgenic mice as well as in a live virus (EcoHIV) rodent model.
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